================================================================================
COLLECTED CLINICAL TRIALS REPORT
================================================================================
Collection Date: 2025-07-22 13:47:35
Total Studies: 138
Studies with Publications: 37
Studies without Publications: 101
Search Query: AREA[Condition](Neuroendocrine Tumors OR Carcinoma Neuroendocrine OR Carcinoid Tumor) AND NOT (AREA[Phase]Phase 1) AND AREA[OverallStatus](ACTIVE_NOT_RECRUITING OR COMPLETED) AND (AREA[HasResults]false) AND AREA[PrimaryCompletionDate] RANGE[2020-01-01,MAX]
Filter Criteria: Neuroendocrine tumor studies, excluding Phase 1
--------------------------------------------------------------------------------

1. Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET
   NCT ID: NCT04385992
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors
   Intervention: 177Lu-Dotatate
   Sponsor: IRCCS San Raffaele
   Start Date: 2020-03-09
   Completion Date: 2023-06-26
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04385992
   Summary: Peptide Receptor Radionuclide Therapy (PRRT) is based on specific somatostatin receptor targeting with radiolabelled analogues 90Y-DOTATOC and 177Lu-DOTATATE. These two most commonly used radiopeptides, 90Y-DOTATOC and 177Lu-DOTATATE, produce overall objective response rates of 15-35%. PRRT is gener...
   Locations: Ospedale San Raffaele, Milano, Italy
----------------------------------------

2. Open-Label Surufatinib in European Patients With NET
   NCT ID: NCT04579679
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumours; Neuroendocrine Tumour of the Lung; Small Intestinal NET
   Intervention: Surufatinib
   Sponsor: Hutchmed
   Start Date: 2021-08-13
   Completion Date: 2024-10-15
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04579679
   Summary: This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low to intermediate grade (Grade 1 or Grade 2), well-differentiated neuroendocrine tumours (NETs).
   Locations: University of Alabama, Birmingham (UAB), Birmingham, United States; University of California Irvine Medical Center UCIMC - H.H. Chao Comprehensive Digestive Disease Center CDDC, Orange, United States; Emory University, Winship Cancer Institute, Atlanta, United States
              ... and 20 more locations
----------------------------------------

3. Routine Transcervical Thymectomy in MEN-1 Patients
   NCT ID: NCT05061784
   Status: COMPLETED
   Phase: N/A
   Condition: Multiple Endocrine Neoplasia Type 1 (MEN-1); Thymic Carcinoid
   Intervention: Routine thymectomy, which has been performed
   Sponsor: National University Health System, Singapore
   Start Date: 2021-07-14
   Completion Date: 2021-08-20
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05061784
   Summary: A case series was built after review of available literature by searching four databases (PubMed, Embase, Medline and Cochrane Library) for observational studies or case reports on routine prophylactic TCT for MEN-1 and the development of thymic carcinoids.
   Locations: National University Hospital, Singapore, Singapore
----------------------------------------

4. Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer
   NCT ID: NCT03360721
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Castration-Resistant Prostate Carcinoma; Prostate Adenocarcinoma Without Neuroendocrine Differentiation; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
   Intervention: Abiraterone Acetate; Apalutamide; Prednisone
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2018-03-06
   Completion Date: 2027-04-30
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03360721
   Summary: This phase II trial studies how well apalutamide and abiraterone acetate work in treating participants with castration resistant prostate cancer that has spread to other places in the body (metastatic). Abiraterone acetate and apalutamide may stop the growth of tumor cells by blocking some of the en...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

5. Investigation of the Effects of Diet on the Measurement of Plasma Chromogranin in NET Patients
   NCT ID: NCT03288402
   Status: COMPLETED
   Phase: NA
   Condition: Neuroendocrine Tumors
   Intervention: ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast
   Sponsor: University Hospitals Coventry and Warwickshire NHS Trust
   Start Date: 2017-02-01
   Completion Date: 2022-02-10
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03288402
   Summary: Measurement of plasma chromogranin A remains the most commonly used biomarkers for both screening and monitoring of patients with gastro-entero-pancreatic neuroendocrine tumours (GEP-NET), despite several limitations that include: lack of a reference CgA standard; wide variations depending on the us...
   Locations: The ARDEN NET Centre, ENETS Centre of Excellence, Coventry, United Kingdom
----------------------------------------

6. Post-Authorization Long-Term Safety Study of LUTATHERA
   NCT ID: NCT03691064
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Condition: Neuroendocrine Tumors
   Intervention: LUTATHERA
   Sponsor: Advanced Accelerator Applications
   Start Date: 2018-11-28
   Completion Date: 2028-06-30
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03691064
   Summary: Study to assess the long-term safety of LUTATHERA for the labeled indication (SmPC/USPI).
   Locations: Banner MD Anderson Cancer Center, Phoenix, United States; The Ohio State University Wexner Medical Center, Portland, United States; Oregon Health & Sciences University Hospital, Portland, United States
              ... and 17 more locations
----------------------------------------

7. Avelumab in G2-3 NET
   NCT ID: NCT03278379
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors
   Intervention: Avelumab
   Sponsor: Sunnybrook Health Sciences Centre
   Start Date: 2017-11-15
   Completion Date: 2023-07-06
   Has Posted Results: False
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03278379
   Summary: This is a single-center, single-arm, open-label, phase II trial to evaluate the efficacy and safety of avelumab in subjects with unresectable or metastatic, Grade 2-3, well-differentiated neuroendocrine.tumour.
   Locations: Sunnybrook Health Sciences Centre, Toronto, Canada
----------------------------------------

8. The Registry of Oncology Outcomes Associated with Testing and Treatment
   NCT ID: NCT04028479
   Status: COMPLETED
   Phase: N/A
   Condition: Adenocarcinoma; Adenocystic Carcinoma; Anal Cancer; Appendix Cancer; Brain Tumor; Glioblastoma; Astrocytoma; Bile Duct Cancer; Cholangiocarcinoma; Bladder Cancer; Bone Cancer; Synovial Sarcoma; Chondrosarcoma; Liposarcoma; Sarcoma, Kaposi; Sarcoma,Soft Tissue; Sarcoma; Osteosarcoma; CNS Cancer; Brain Stem Neoplasms; Breast Cancer; Cervical Cancer; Colorectal Cancer; Rectal Cancer; Colon Cancer; Esophageal Cancer; Esophagus Cancer; Cancer of Colon; Pancreatic Cancer; Cancer of Pancreas; Testis Cancer; Testicular Cancer; Ureter Cancer; Renal Cell Carcinoma; Kidney Cancer; Gestational Trophoblastic Tumor; Head and Neck Neoplasms; Parotid Tumor; Larynx Cancer; Tongue Cancer; Pharynx Cancer; Salivary Gland Cancer; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Multiple Myeloma; Non Hodgkin Lymphoma; Carcinoid Tumor; Lung Cancer; Neuroendocrine Tumors; Mesothelioma; Thyroid Cancer; Parathyroid Neoplasms; Adrenal Cancer; Small Bowel Cancer; Stomach Cancer; Liver Cancer; Hepatic Cancer; Melanoma; Skin Cancer; Unknown Primary Tumors; Uterine Cancer; Fallopian Tube Cancer; Ovarian Cancer; Prostate Cancer; Vaginal Cancer; Penile Cancer; Vulvar Cancer; Waldenstrom Macroglobulinemia; Cancer, Advanced; Thymus Cancer; Nasopharyngeal Carcinoma; Multiple Endocrine Neoplasia; Pheochromocytoma; Small Cell Carcinoma; Pulmonary Carcinoma
   Intervention: Biomarker Testing (L); Systemic Treatment (T); Patient Reported Outcomes (P)
   Sponsor: Taproot Health
   Start Date: 2021-05-05
   Completion Date: 2024-10-31
   Has Posted Results: False
   Publications Count: 9
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04028479
   Summary: This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. It will also create reusable infrastructure to allow creation or affiliation with many a...
   Locations: Teton Cancer Institute, Idaho Falls, United States; Oncology and Hematology of South Texas, Laredo, United States
----------------------------------------

9. Neuroendocrine Tumors - Patient Reported Outcomes
   NCT ID: NCT05064150
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Condition: Neuroendocrine Tumors; Gastroenteropancreatic Neuroendocrine Tumor; Lung Neuroendocrine Neoplasm; Neuroendocrine Carcinoma
   Intervention: 
   Sponsor: University of Iowa
   Start Date: 2022-05-10
   Completion Date: 2026-06
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05064150
   Summary: With so many therapeutic options available (i.e.: biologic therapy, liver directed therapy, radiotherapy and chemotherapy), the purpose of this project is to partner with patients on comparative effectiveness research (CER) to achieve the goal of alleviating undue toxicity, and optimizing effectiven...
   Locations: University of Florida, Gainesville, United States; University of Iowa, Iowa City, United States; University of Kansas Medical Center Research Institute, Inc, Kansas City, United States
              ... and 11 more locations
----------------------------------------

10. A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung
   NCT ID: NCT05470595
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Large Cell Neuroendocrine Carcinoma of the Lung
   Intervention: Atezolizumab
   Sponsor: Technische Universität Dresden
   Start Date: 2022-01-18
   Completion Date: 2029-01-31
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05470595
   Summary: This phase II clinical trial evaluates the efficacy, safety and tolerability of Atezolizumab in addition to standard of care chemotherapy (Platinum/Etoposide) in LCNEC.
   Locations: Charité - Universitätsklinikum Berlin Centrum 12, Medizinische Klinik, Berlin, Germany; Evangelische Lungenklinik, Berlin, Germany; Universitätsklinikum Dresden, Medizinische Klinik 1, Dresden, Germany
              ... and 12 more locations
----------------------------------------

11. Clinical Application of the Prototype J-PET Device
   NCT ID: NCT06211803
   Status: COMPLETED
   Phase: N/A
   Condition: Neurodegenerative Diseases; Brain Neoplasms; Neuroendocrine Tumors
   Intervention: Positron-Emission Tomography Imaging
   Sponsor: Jagiellonian University
   Start Date: 2022-03-11
   Completion Date: 2022-03-22
   Has Posted Results: False
   Publications Count: 5
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06211803
   Summary: Positron emission tomography (PET) is a diagnostic imaging technique that uses positron emission (e-) to image changes in diagnosed tissues. Detector systems are an important part of PET scanners. They can convert gamma photons into fluorescent photons to obtain information about energy, time and po...
   Locations: Department of Nuclear Medicine, Warsaw, Poland
----------------------------------------

12. Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
   NCT ID: NCT03891784
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Advanced Digestive System Neuroendocrine Neoplasm; Digestive System Neuroendocrine Tumor; Foregut Neuroendocrine Tumor; Hindgut Neuroendocrine Tumor; Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm; Metastatic Digestive System Neuroendocrine Neoplasm; Midgut Neuroendocrine Tumor; Pancreatic Neuroendocrine Tumor; Refractory Digestive System Neuroendocrine Neoplasm
   Intervention: Abemaciclib
   Sponsor: University of Washington
   Start Date: 2019-10-31
   Completion Date: 2027-09-30
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03891784
   Summary: This phase II trial studies how well abemaciclib works in treating patients with digestive system neuroendocrine tumors that have spread to other places in the body, do not respond to treatment, and cannot be removed by surgery. Abemaciclib may stop the growth of tumor cells by blocking some of the ...
   Locations: University of Colorado, Denver, United States; Fred Hutch/University of Washington Cancer Consortium, Seattle, United States
----------------------------------------

13. A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)
   NCT ID: NCT04438304
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors
   Intervention: 64Cu-SARTATE
   Sponsor: Clarity Pharmaceuticals Ltd
   Start Date: 2021-03-02
   Completion Date: 2024-11-26
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04438304
   Summary: The purpose of this study is to assess the performance of imaging agent 64Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs) as a potential new way to help diagnose NETs.
   Locations: Nepean Hospital, Kingswood, Australia; Royal North Shore Hospital, Sydney, Australia; Royal Adelaide Hospital, Adelaide, Australia
              ... and 1 more locations
----------------------------------------

14. Community-based Neuroendocrine Tumor (NET) Research Study
   NCT ID: NCT02730104
   Status: COMPLETED
   Phase: N/A
   Condition: Gastroenteropancreatic Neuroendocrine Tumors
   Intervention: 
   Sponsor: Ipsen
   Start Date: 2015-11-23
   Completion Date: 2020-05-13
   Has Posted Results: False
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02730104
   Summary: The purpose of this trial is to assess time to disease progression of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors treated with Lanreotide Depot. This is an observational study therefore all data collected will be in accordance with the routine practice o...
   Locations: Arizona Oncology Associates, Sedona, United States; Rocky Mountain Cancer Centers, Denver, United States; Illinois Cancer Specialists, Arlington Heights, United States
              ... and 9 more locations
----------------------------------------

15. Optimising Molecular Radionuclide Therapy
   NCT ID: NCT04922801
   Status: COMPLETED
   Phase: N/A
   Condition: Neuroendocrine Tumors; Hyperthyroidism; Thyroid Cancer; Thyroid Carcinoma
   Intervention: Nuclear Medicine whole-body; SPECT/CT imaging.; PET/CT imaging.; Patient-led radiation monitor (SELFIE); LAB TEST
   Sponsor: King's College London
   Start Date: 2021-12-09
   Completion Date: 2022-11-05
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04922801
   Summary: This project will examine the role of the whole body, PET and SPECT imaging before, during and after radionuclide treatment for 177Lu-Dotatate therapy, whole body and SPECT imaging for 131-I for thyroid cancer therapy, and whole-body imaging for 131I for hyperthyroidism therapy. Whole-body and SPECT...
   Locations: Guy's and St Thomas Hospitals Foundation Trust, London, United Kingdom
----------------------------------------

16. Whole Body Dynamic 68Ga-DOTATOC PET/CT in Neuroendocrine Tumors
   NCT ID: NCT03576040
   Status: COMPLETED
   Phase: N/A
   Condition: Neuroendocrine Tumors
   Intervention: Whole Body Dynamic 68Ga-DOTATOC PET/CT
   Sponsor: University Hospital, Brest
   Start Date: 2018-07-19
   Completion Date: 2023-07-06
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03576040
   Summary: Neuroendocrine tumors (NET) are a network of rare tumors with common embryological origin. Functional imaging plays a major role in the extension assessment and tumor characterization of NETs. SPECT/CT with 111In-pentetreotide is the recommended test when tumors are well differentiated (grade G1 or ...
   Locations: CHRU de Brest, Brest, France
----------------------------------------

17. Circulating Tumor Cells and Tumor DNA in HCC and NET
   NCT ID: NCT02973204
   Status: COMPLETED
   Phase: N/A
   Condition: Carcinoma, Hepatocellular; Neuroendocrine Tumors
   Intervention: Sorafenib; Radiofrequency ablation (RFA) or surgery; Everolimus; Lanreotide
   Sponsor: University of Aarhus
   Start Date: 2016-11
   Completion Date: 2020-01-08
   Has Posted Results: False
   Publications Count: 16
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02973204
   Summary: Background Treatment and control of cancer is associated with high costs, to patients in the form of side effects and discomfort during investigations, to society in the form of expensive drugs and studies.

Circulating tumor cells (CTC) has received great attention as a cancer biomarker in trying t...
   Locations: Department of Hepatology and Gastroenterology, Aarhus, Denmark
----------------------------------------

18. Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
   NCT ID: NCT04584008
   Status: ACTIVE_NOT_RECRUITING
   Phase: NA
   Condition: Biliary Tract Neoplasms; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Colorectal Cancer; Gastrointestinal Stromal Tumors; Pancreatic Cancer; Neuroendocrine Tumors; Unknown Primary Cancer; Digestive Cancer
   Intervention: FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.; Other Therapy
   Sponsor: Peking University
   Start Date: 2020-09-23
   Completion Date: 2025-03
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04584008
   Summary: This a prospective real-world navigation study using tumor DNA sequencing technology to sequence genes of previously treated and refractory gastrointestinal tumors, which are generally considered to be highly heterogeneous and complex, to screen potential molecular targeted drugs for individualized ...
   Locations: Peking University Cancer Hospital, Beijing, China
----------------------------------------

19. Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or Reconstruction
   NCT ID: NCT06024343
   Status: COMPLETED
   Phase: NA
   Condition: Pancreatic Tumor, Benign; Pancreatic Neuroendocrine Tumor; Solid Pseudopapillary Tumor of the Pancreas
   Intervention: MPD Exposure, Repair or Reconstruction
   Sponsor: Fudan University
   Start Date: 2019-07-01
   Completion Date: 2024-08-31
   Has Posted Results: False
   Publications Count: 14
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06024343
   Summary: The aim of this study is to evaluate the impact of concomitant main pancreatic duct exposure, repair, or reconstruction during minimally invasive pancreatic tumor enucleation on long-term patient prognosis and quality of life.
   Locations: Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
----------------------------------------

20. Cohort of Well-differentiated Grade 3 Neuroendocrine Digestive Tumors
   NCT ID: NCT04365023
   Status: COMPLETED
   Phase: N/A
   Condition: Neuroendocrine Tumors
   Intervention: platinum chemotherapy
   Sponsor: Assistance Publique - Hôpitaux de Paris
   Start Date: 2020-07-02
   Completion Date: 2023-05-25
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04365023
   Summary: The purpose of this study is to analyse clinical data of well-differentiated grade 3 digestive neuroendocrine tumors. These rare tumors may have a different disease evolution, response to chemotherapy and prognostic.
   Locations: Gastroenterology and digestive oncology unit - Cochin hospital, Paris, France
----------------------------------------

21. Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
   NCT ID: NCT04727723
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Condition: Gastroenteropancreatic Neuroendocrine Tumor
   Intervention: Lutathera®
   Sponsor: Advanced Accelerator Applications
   Start Date: 2021-03-09
   Completion Date: 2025-04-01
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04727723
   Summary: This is a multicentre long-term non-interventional study of adult subjects diagnosed with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive GEP-NETs who have been prescribed Lutathera® in standard clinical practice.
   Locations: Novartis Investigative Site, Alessandria, Italy; Novartis Investigative Site, Bologna, Italy; Novartis Investigative Site, Brescia, Italy
              ... and 15 more locations
----------------------------------------

22. Inhaled Essential Oil Effect on Common QOL Concerns During Cancer Treatment
   NCT ID: NCT03858855
   Status: COMPLETED
   Phase: NA
   Condition: Gastrointestinal Cancer; Neuroendocrine Carcinoma; Skin Cancer
   Intervention: Aromatherapy and Essential Oils; Aromatherapy and Essential Oils; Aromatherapy and Essential Oils; Aromatherapy and Essential Oils; Subject Diary
   Sponsor: Ohio State University Comprehensive Cancer Center
   Start Date: 2019-02-18
   Completion Date: 2020-04-13
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03858855
   Summary: This single-blind, randomized controlled trial studies how well inhaled essential oils work for common quality of life concerns in patients who are undergoing cancer treatment such as chemotherapy, targeted therapy, and/or immunotherapy given through the vein (intravenously). Aromatherapy using esse...
   Locations: Ohio State University Comprehensive Cancer Center, Columbus, United States
----------------------------------------

23. A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3
   NCT ID: NCT04524208
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Neuroendocrine Carcinoma
   Intervention: Cabozantinib
   Sponsor: Karsten Gavenis
   Start Date: 2021-03-01
   Completion Date: 2024-10-31
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04524208
   Summary: The main objective of this clinical trial represents the evaluation of efficacy of the tyrosine kinase inhibitor Cabozantinib in patients with NEN G3 with a proliferation rate of Ki67 20 - 60%.
   Locations: Medizinische Universität Wien, Wien, Austria; University Medical Center Göttingen, Göttingen, Germany; Zentralklinik Bad Berka GmbH, Bad Berka, Germany
              ... and 12 more locations
----------------------------------------

24. Pancreatic Fistula After Minimally Invasive Enucleation
   NCT ID: NCT06557408
   Status: COMPLETED
   Phase: N/A
   Condition: Pancreatic Tumor, Benign; Pancreatic Neuroendocrine Tumor; Solid Pseudopapillary Tumor of the Pancreas
   Intervention: 
   Sponsor: Fudan University
   Start Date: 2019-07-01
   Completion Date: 2024-07-30
   Has Posted Results: False
   Publications Count: 9
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06557408
   Summary: Patients suffering from postoperative pancreatic fistula (POPF) after minimally invasive enucleation (MIEN) show a characteristic pattern of longer duration and milder symptoms, which is different from pancreatic fistula after standard pancreatectomy. This study aimed to analyze the factors influenc...
   Locations: Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center Shanghai, Shanghai, China, Shanghai, China
----------------------------------------

25. The Role of Intraoperative Hepatic Ultrasonography in Gastrointestinal or Pancreatic Neuroendocrine Tumor
   NCT ID: NCT06779708
   Status: COMPLETED
   Phase: N/A
   Condition: Neuroendocrine (NE) Tumors; Liver Metastasis
   Intervention: 
   Sponsor: Istituto Clinico Humanitas
   Start Date: 2020-10-01
   Completion Date: 2023-12-31
   Has Posted Results: False
   Publications Count: 9
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06779708
   Summary: Background: Liver metastases are common in patients with neuroendocrine neoplasms, but often underestimated by preoperative imaging. Intraoperative ultrasound (IOUS) is the reference standard for staging of primary and metastatic liver tumors, with a diagnostic accuracy superior to that of CT and MR...
   Locations: Humanitas Research Hospital, Rozzano, Italy
----------------------------------------

26. Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease
   NCT ID: NCT05064514
   Status: ACTIVE_NOT_RECRUITING
   Phase: NA
   Condition: Tricuspid Regurgitation; Tricuspid Valve Disease; Carcinoid Syndrome; Carcinoid Heart Disease
   Intervention: Transcatheter Tricuspid Valved Stent Graft
   Sponsor: Queen Mary University of London
   Start Date: 2022-04-06
   Completion Date: 2028-03
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05064514
   Summary: The purpose of this investigation is to see if the TRICENTO Valved Stent Graft implant reduces tricuspid regurgitation (TR) and improves the symptoms and quality of life in 15 participants with carcinoid heart disease, and who are not able to have a new valve via a surgical procedure.
   Locations: Barts Health NHS Trust, London, United Kingdom
----------------------------------------

27. A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
   NCT ID: NCT05017662
   Status: COMPLETED
   Phase: NA
   Condition: Neuroendocrine Tumors
   Intervention: Data collection
   Sponsor: Ariceum Therapeutics GmbH
   Start Date: 2021-09-14
   Completion Date: 2025-04-29
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05017662
   Summary: The purpose of the protocol is to evaluate the long-term safety of medicine 177Lu-satoreotide tetraxetan (also known as 177Lu-IPN01072 or 177Lu-OPS201) for patients who have previously received 177Lu-satoreotide tetraxetan in the clinical study OPS-C-001 / D-FR-01072-001.
   Locations: Peter Maccallum Cancer Center, Melbourne, Australia; Ramsay Hollywood Private Hospital, Perth, Australia; Medical University of Vienna, Vienna, Austria
              ... and 4 more locations
----------------------------------------

28. Ki67 Proliferation Index of Pancreatic Neuroendocrine Neoplasia
   NCT ID: NCT04753229
   Status: COMPLETED
   Phase: N/A
   Condition: Neuroendocrine Tumors
   Intervention: 
   Sponsor: Institut Paoli-Calmettes
   Start Date: 2008-01-01
   Completion Date: 2020-10-01
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04753229
   Summary: This is a retrospective, monocentric study involving 50 patients with pancreatic neuroendocrine neoplasia resected between January 2008 and June 2020 at Paoli Calmettes Institute.

The primary objective of the study is to evaluate the grade concordance rate, based on Ki67 obtained on the pre-operati...
----------------------------------------

29. United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting
   NCT ID: NCT04649580
   Status: COMPLETED
   Phase: N/A
   Condition: Neuroendocrine Tumours (NET)
   Intervention: 
   Sponsor: Ipsen
   Start Date: 2021-04-27
   Completion Date: 2022-06-05
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04649580
   Summary: The aim of the study is to generate real-world evidence to describe the patient experience of administration of Somatuline® Autogel® (lanreotide) in homecare and hospital settings, and the associated impact on healthcare utilisation, societal cost, work productivity and health-related quality of lif...
   Locations: University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; Cardiff and Vale University LHB, Cardiff, United Kingdom; University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom
              ... and 2 more locations
----------------------------------------

30. 18F-AmBF3-TATE PET/CT for Imaging NET Patients
   NCT ID: NCT04207762
   Status: COMPLETED
   Phase: N/A
   Condition: Neuroendocrine Tumors
   Intervention: 18F-AmBF3-TATE PET/CT; Routine blood draw
   Sponsor: British Columbia Cancer Agency
   Start Date: 2020-06-09
   Completion Date: 2021-01-15
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04207762
   Summary: Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called somatostatin receptors (SSTR). Somatostatin receptor scintigraphy and conventi...
   Locations: BC Cancer, Vancouver, Canada
----------------------------------------

31. Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
   NCT ID: NCT06908629
   Status: ACTIVE_NOT_RECRUITING
   Phase: NA
   Condition: Cancer; Cancer Survivors; Gastrointestinal Cancers; Neuroendocrine Tumors; Multiple Myeloma, Neoplasms
   Intervention: Implementation of social determinants of health screening and referral
   Sponsor: Barbara Ann Karmanos Cancer Institute
   Start Date: 2024-07-01
   Completion Date: 2025-05
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06908629
   Summary: The goal of this screening study is to determine the feasibility of completing a social needs screening tool in participants who have a past or current cancer diagnosis and reside in Metro Detroit, Michigan. Main questions to answer are:

* Can we have a completion rate of at least 80% of participan...
   Locations: Karmanos Cancer Institute, Detroit, United States
----------------------------------------

32. A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
   NCT ID: NCT05459844
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Condition: Neuroendocrine Tumors
   Intervention: Lutetium[177Lu] Oxodotreotide Injection; Octreotide LAR
   Sponsor: Sinotau Pharmaceutical Group
   Start Date: 2022-08-31
   Completion Date: 2028-12
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05459844
   Summary: This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutetium\[177Lu\] Oxodotreotide Injection to high dose (60 mg) Octreotide LAR in patients with unresectable or metastatic, progressive, well differentiated (G1 and G2)...
   Locations: Chinese PLA General Hospital, Beijing, China; The First Afilliated Hospital of Fujian Medical University, Fuzhou, China; The First Affiliated Hospital of Xiamen University, Xiamen, China
              ... and 20 more locations
----------------------------------------

33. Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel
   NCT ID: NCT03562091
   Status: COMPLETED
   Phase: N/A
   Condition: Neuroendocrine Tumors
   Intervention: Data collection
   Sponsor: Ipsen
   Start Date: 2018-07-20
   Completion Date: 2020-05-15
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03562091
   Summary: The purpose of the study is to evaluate, in standard practice, the change in information received and perceived by the patient, extension of the disease and its treatment. These parameters will be evaluated by means of validated self-administered questionnaires that can be used in standard practice.
   Locations: Ipsen Central Contact, Paris, France
----------------------------------------

34. Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
   NCT ID: NCT04810091
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Condition: Locally Advanced Neuroendocrine Neoplasm; Metastatic Neuroendocrine Neoplasm
   Intervention: Placebo Administration; Questionnaire Administration; Telotristat Ethyl
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2021-05-18
   Completion Date: 2025-08-26
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04810091
   Summary: This phase III trial compares the effect of telotristat ethyl and the current standard of care somatostatin analog therapy or somatostatin analog therapy alone in treating patients with neuroendocrine tumor that has spread to other places in the body (metastatic). Telotristat ethyl and somatostatin ...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

35. Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
   NCT ID: NCT05816720
   Status: COMPLETED
   Phase: N/A
   Condition: Neuroendocrine Tumor
   Intervention: Lutetium-177 DOTATATE
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2021-09-01
   Completion Date: 2022-01-31
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05816720
   Summary: This was a retrospective non-interventional study evaluating the medical records of patients with neuroendocrine tumor (NET) re-treated with lutetium-177 DOTATATE at a single United States institution - the Excel Diagnostics \& Nuclear Oncology Center in Houston, Texas. Initial treatment was defined...
   Locations: Excel Diagnostics & Nuclear Oncology Center, Houston, United States
----------------------------------------

36. Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
   NCT ID: NCT03012620
   Status: COMPLETED
   Phase: PHASE2
   Condition: Sarcoma; Ovarian Neoplasm; Central Nervous System Neoplasm; Thyroid Neoplasm; Carcinoma, Neuroendocrine; Neoplasms, Germ Cell and Embryonal; NK/T-cell Lymphoma
   Intervention: Pembrolizumab
   Sponsor: UNICANCER
   Start Date: 2017-07-05
   Completion Date: 2023-12-14
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03012620
   Summary: This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of pembrolizumab monotherapy in 7 cohorts of patients with specific rare cancers who have unresectable locally advanced or metastatic disease, which is resistant or refractory to standard therapy...
   Locations: Gustave Roussy Cancer Campus, Villejuif, France
----------------------------------------

37. Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms
   NCT ID: NCT05871320
   Status: COMPLETED
   Phase: EARLY_PHASE1
   Condition: Neuroendocrine Tumors
   Intervention: [99mTc]Tc-TECANT1
   Sponsor: Jagiellonian University
   Start Date: 2022-12-23
   Completion Date: 2023-06-30
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05871320
   Summary: The main goal of the study is to expand cancer preclinical research results on the usefulness of SSTR2-Antagonist \[99mTc\]Tc-TECANT1 in clinical practice. Detection of NEN and monitoring of response to therapy is still challenging due to their cellular heterogeneity. Initial preclinical studies sug...
   Locations: Innsbruck Medical University Department of Nuclear Medicine, Innsbruck, Austria; Department of Endocrinology, Jagiellonian University Medical College, Kraków, Poland; University Medical Centre Ljubljana Department of Nuclear Medicine, Ljubljana, Slovenia
----------------------------------------

38. Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II
   NCT ID: NCT02230176
   Status: COMPLETED
   Phase: PHASE2
   Condition: Pancreatic Neuroendocrine Carcinoma
   Intervention: Sunitinib; 177Lu-DOTA0-Tyr3-Octreotate
   Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
   Start Date: 2015-02
   Completion Date: 2024-04
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02230176
   Summary: This study is the first randomized, open-label, national, multicenter, phase II study assessing the efficacy and safety of OCLU in subjects with pretreated progressive pancreatic, inoperable, somatostatin receptor positive, well differentiated pancreatic neuroendocrine tumors (WDpNET). Subjects must...
   Locations: Gustave Roussy, Villejuif, France
----------------------------------------

39. Nutrition in Gastrointestinal Tumors
   NCT ID: NCT04476082
   Status: COMPLETED
   Phase: N/A
   Condition: Pancreatic Cancer; Oesophageal Cancer; Colon Cancer; Liver Cancer; Rectal Cancer; Bile Duct Cancer; GIST, Malignant; Neuroendocrine Tumors; Small Intestine Cancer; Gastric Cancer
   Intervention: No intervention - observational study only
   Sponsor: University Medicine Greifswald
   Start Date: 2020-06-25
   Completion Date: 2022-12-06
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04476082
   Summary: Malnutrition and loss of muscle mass frequently occur in patients undergoing chemotherapy and can negatively effect therapy outcome. Especially patients with cancer of the gastrointestinal tract are often affected by malnutrition. Therefore, this study aims to examine changes in nutritional status o...
   Locations: University Medicine Greifswald, Greifswald, Germany
----------------------------------------

40. Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)
   NCT ID: NCT03591731
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Carcinoma
   Intervention: Nivolumab; Ipilimumab
   Sponsor: Intergroupe Francophone de Cancerologie Thoracique
   Start Date: 2019-01-02
   Completion Date: 2024-12-15
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03591731
   Summary: Neuroendocrine tumors of the lung include the small cell carcinoma (SCLC), and large cell neuroendocrine carcinoma (LCNEC) and represent 20% of lung cancer. One of the only studies reported to date is reporting on a progression-free survival (PFS) and overall survival (OS) of 5.2 months and 7.7 mont...
   Locations: Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHU d'Amiens-Picardie, Amiens, France; CHU d'Angers, Angers, France
              ... and 4 more locations
----------------------------------------

41. Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
   NCT ID: NCT03049189
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Condition: Neuroendocrine Tumors
   Intervention: 177Lu-edotreotide PRRT; Everolimus; Amino-Acid Solution
   Sponsor: ITM Solucin GmbH
   Start Date: 2017-02-02
   Completion Date: 2029-11
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03049189
   Summary: The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastro...
   Locations: Banner Health d.b.a. Banner MD Anderson Cancer Center, Gilbert, United States; Stanford University, Stanford, United States; Moffitt Cancer Center & Research Institute, Tampa, United States
              ... and 49 more locations
----------------------------------------

42. Surgical Intervention and the NETest
   NCT ID: NCT03012789
   Status: ACTIVE_NOT_RECRUITING
   Phase: NA
   Condition: Neuroendocrine Tumor; Gastroenteropancreatic
   Intervention: Surgery
   Sponsor: Wren Laboratories LLC
   Start Date: 2017-05-15
   Completion Date: 2026-06
   Has Posted Results: False
   Publications Count: 3
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03012789
   Summary: The purpose of this study is to evaluate the effect of different surgical resections (R0, R1, R2) on circulating NET transcripts (PCR score or NETest). A drop in circulating NET levels will be correlated with surgical excision. Secondly, variation of circulating NET transcripts will be correlated to...
   Locations: San Raffaele Hospital IRCCS, Milano, Italy
----------------------------------------

43. Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
   NCT ID: NCT04919226
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Condition: Neuroendocrine Tumors
   Intervention: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT; CAPTEM (Capecitabine and Temozolomide); Amino-Acid Solution; Everolimus; FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
   Sponsor: ITM Solucin GmbH
   Start Date: 2021-12-21
   Completion Date: 2027-09
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04919226
   Summary: The purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, soma...
   Locations: Stanford Cancer Center, Palo Alto, United States; University of Colorado Hospital, Nuclear Medicine, Aurora, United States; H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States
              ... and 39 more locations
----------------------------------------

44. Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
   NCT ID: NCT03333616
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Genitourinary Cancer; Adrenocortical Carcinoma; Non-urothelial Bladder; Non-urothelial Upper Tract; Penile Cancer; Non-adenocarcinoma Prostate Cancer; Refractory Germ-cell; High Grade Neuroendocrine Carcinoma/Small Cell Carcinoma
   Intervention: Ipilimumab; Nivolumab
   Sponsor: Dana-Farber Cancer Institute
   Start Date: 2017-12-28
   Completion Date: 2026-05-31
   Has Posted Results: False
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03333616
   Summary: This research study is studying a combination of drugs as a possible treatment for rare genitourinary malignancies among four cohorts, bladder or upper tract carcinoma with variant histology, adrenocortical carcinoma, other rare genitourinary carcinomas and any genitourinary carcinoma with neuroendo...
   Locations: University of California, San Diego Moores Cancer Center, La Jolla, United States; Winship Cancer Institute, Emory University, Atlanta, United States; Beth Israel Deaconess Medical Center, Boston, United States
              ... and 3 more locations
----------------------------------------

45. Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
   NCT ID: NCT02568267
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Melanoma; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Primary Brain Tumors; Renal Cell Carcinoma; Sarcomas; Salivary Gland Cancers; Adult Solid Tumor
   Intervention: Entrectinib
   Sponsor: Hoffmann-La Roche
   Start Date: 2015-11-19
   Completion Date: 2025-12-31
   Has Posted Results: False
   Publications Count: 6
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02568267
   Summary: This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.
   Locations: Dignity Health St Joseph's Hospital and Medical Center, Phoenix, United States; Mayo Clinic, Phoenix, United States; City of Hope Cancer Center, Duarte, United States
              ... and 125 more locations
----------------------------------------

46. Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors
   NCT ID: NCT02586844
   Status: COMPLETED
   Phase: N/A
   Condition: Neuroendocrine Tumors; Pancreatic Neuroendocrine Tumors
   Intervention: 
   Sponsor: University Health Network, Toronto
   Start Date: 2013-10
   Completion Date: 2021-04
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02586844
   Summary: Prospective study to obtain fresh tumor biopsies and three blood samples from patients with a confirmed histological or cytological diagnosis of well-differentiated neuroendocrine tumors (NETs) or well-differentiated pancreatic neuroendocrine tumors (PanNETs) for molecular profiling.
   Locations: Princess Margaret Cancer Centre, Toronto, Canada
----------------------------------------

47. EchoTip AcuCore Post-Market Clinical Study
   NCT ID: NCT06358001
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Condition: Adenocarcinoma; Neuroendocrine Tumors; Hepatocellular Carcinoma; Cholangiocarcinoma; Malignant Lymphoma; Metastasis; Chronic Pancreatitis; Autoimmune Pancreatitis
   Intervention: EchoTip AcuCore
   Sponsor: Cook Research Incorporated
   Start Date: 2024-08-05
   Completion Date: 2025-09-01
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06358001
   Summary: The purpose of collecting this data is to continue to learn more about the EchoTip AcuCore and the device's ability to produce the desired favorable effect and if there are any undesired outcomes that may be related to the EchoTip AcuCore.
   Locations: University of California, Irvine, Orange, United States; Advent Health, Porter, Denver, United States; Shands Hospital-University of Florida, Gainesville, United States
              ... and 5 more locations
----------------------------------------

48. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver
   NCT ID: NCT02724540
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumor, Malignant; Liver Metastases
   Intervention: Bland Embolization; Transarterial chemoembolization; Drug Eluting Beads Embolization
   Sponsor: Abramson Cancer Center at Penn Medicine
   Start Date: 2016-03
   Completion Date: 2024-11-08
   Has Posted Results: False
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02724540
   Summary: The primary aim of this trial is to estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembo...
   Locations: University of California San Francisco, San Francisco, United States; Stanford University, Standford, United States; Moffitt Cancer Center, Tampa, United States
              ... and 10 more locations
----------------------------------------

49. TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors
   NCT ID: NCT03079440
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Neuroendocrine Carcinoma; Temozolomide; Capecitabine
   Intervention: TEMCAP
   Sponsor: Asan Medical Center
   Start Date: 2017-05-15
   Completion Date: 2022-11-15
   Has Posted Results: False
   Publications Count: 5
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03079440
   Summary: GI tract including pancreas is the one of most common primary sites of neuroendocrine tumors. Current grading of neuroendocrine tumors are based on the 2010 WHO classification. This classifies grade 3 tumors as the neuroendocrine tumor with mitosis \> 20 per 10 high power field or Ki-67 labeling ind...
   Locations: Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
----------------------------------------

50. A Real-world Comparison of FNB and FNA in IHC-required Lesions.
   NCT ID: NCT05565066
   Status: COMPLETED
   Phase: N/A
   Condition: Neuroendocrine Tumors; Autoimmune Pancreatitis; Gastrointestinal Stromal Tumors
   Intervention: FNB group; FNA group
   Sponsor: Huazhong University of Science and Technology
   Start Date: 2014-12-01
   Completion Date: 2022-10-31
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05565066
   Summary: Endoscopic ultrasound (EUS)-guided fine needles with side fenestrations are used to collect aspirates for cytology analysis and biopsy samples for histologic analysis. The investigators conducted a large, multicenter study to compare the accuracy of diagnosis via specimens collected with fine-needle...
   Locations: Tongji Hospital, Tongji Medical College, HUST, Wuhan, China
----------------------------------------

51. Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors
   NCT ID: NCT05168631
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Condition: Neuroendocrine Tumors; Carcinoma;Endocrine
   Intervention: 
   Sponsor: Latin American Cooperative Oncology Group
   Start Date: 2020-05-16
   Completion Date: 2025-03-15
   Has Posted Results: False
   Publications Count: 15
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05168631
   Summary: Multicenter retrospective longitudinal analytical study of patients with neuroendocrine tumors.
   Locations: Ensino E Terapia de Inovacao Clinica Amo - Etica, Salvador, Brazil; Universidade Federal do Ceará/HOSPITAL UNIVERSITARIO WALTER CANTIDIO, Fortaleza, Brazil; Hospital Sírio Libanês Brasília, Brasília, Brazil
              ... and 4 more locations
----------------------------------------

52. Agnostic Therapy in Rare Solid Tumors
   NCT ID: NCT06638931
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Urachal Cancer; Parathyroid Carcinoma; Fibrolamellar Carcinoma; Angiosarcoma; Secretory Carcinoma of Breast; Anal Neoplasms; Metaplastic Breast Carcinoma; Translocation Renal Cell Carcinoma; Carcinosarcoma; Small Intestine Neoplasms; Cholangiocarcinoma; Sertoli-Leydig Cell Tumor; Adenoid Cystic Carcinoma; Mesothelioma; Neuroblastoma; Adrenal Gland Neoplasms; Penile Neoplasms; Apocrine Carcinoma; Fibrosarcoma; Cancer of Unknown Primary; Hemangioblastoma; Thyroid Neoplasms; Hepatoblastoma; Fallopian Tube Neoplasms; Leiomyosarcoma; Vaginal Neoplasms; Neurofibrosarcoma; Gallbladder Neoplasms; Osteosarcoma; Biliary Tract Neoplasms; Clear Cell Endometrial Cancer; Yolk Sac Tumor; Vulvar Neoplasms; Kaposi Sarcoma; Ovarian Epithelial Cancer; Soft Tissue Sarcoma; Urethral Neoplasms; Granulosa Cell Tumor; Primitive Neuroectodermal Tumor; Neuroendocrine Tumors; Trophoblastic Tumor
   Intervention: Nivolumab
   Sponsor: Instituto do Cancer do Estado de São Paulo
   Start Date: 2024-07-01
   Completion Date: 2028-05
   Has Posted Results: False
   Publications Count: 8
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06638931
   Summary: The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.

The study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), regardless of the tumor's t...
   Locations: Hospital São Rafael, Salvador, Brazil; Hospital São Carlos, Fortaleza, Brazil; Hospital Santa Cruz, Curitiba, Brazil
              ... and 5 more locations
----------------------------------------

53. Pancreatic Cancer Dietary Assessment Study
   NCT ID: NCT03616431
   Status: COMPLETED
   Phase: N/A
   Condition: Pancreatic Neoplasm; Pancreas Adenocarcinoma; Well-Differentiated Neuroendocrine Carcinoma; Malignant Neoplasm of Pancreas
   Intervention: Pancreo-KIT breath test
   Sponsor: The Christie NHS Foundation Trust
   Start Date: 2018-07-03
   Completion Date: 2021-05-31
   Has Posted Results: False
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03616431
   Summary: This is a prospective observational study which aims to evaluate;

The prevalence of pancreatic insufficiency in patients with pancreatic malignancies (adenocarcinoma and neuroendocrine tumours).

The most appropriate diagnostic strategy. The impact that an adequate diagnosis and treatment may have ...
   Locations: The Christie NHS Foundation Trust, Manchester, United Kingdom
----------------------------------------

54. Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-study
   NCT ID: NCT05013957
   Status: COMPLETED
   Phase: N/A
   Condition: Neuroendocrine Tumors
   Intervention: Methylation analysis
   Sponsor: University Hospital, Basel, Switzerland
   Start Date: 2022-01-01
   Completion Date: 2024-12-30
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05013957
   Summary: Neuroendocrine neoplasms (NEN) are rare tumors that mainly occur in the gastrointestinal tract and the lungs. The currently available diagnostic and prognostic markers do not adequately represent the diversity of these tumors. Methylation analyzes of the tumor DNA represent a new, promising approach...
   Locations: University Hospital Basel, Department of Endocrinology, Basel, Switzerland
----------------------------------------

55. PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2
   NCT ID: NCT03271281
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors
   Intervention: One injection of 68Ga-NODAGA-E[c(RGDyK)]2; PET/CT
   Sponsor: Rigshospitalet, Denmark
   Start Date: 2017-12-04
   Completion Date: 2021-12-31
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03271281
   Summary: The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of angiogenesis PET/CT with the radioligand 68Ga-NODAGA- E\[c(RGDyK)\]2 in patients with neuroendocrine tumors (NETs).
   Locations: Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, Denmark
----------------------------------------

56. Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients
   NCT ID: NCT05153772
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Neuroendocrine Tumors
   Intervention: AlphaMedix
   Sponsor: Orano Med LLC
   Start Date: 2021-12-21
   Completion Date: 2028-10
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05153772
   Summary: Multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive somatostatin positive neuroendocrine tumors with either no prior history of peptide receptor radionuclide therapy (PRRT naive) or prior history of peptide receptor radionuclide therapy (Previous PRRT)
   Locations: Rocky Mountain Cancer Center, Denver, United States; Moffitt Cancer Center, Tampa, United States; Louisiana State University (LSU) Health Sciences Center - New Orleans, Metairie, United States
              ... and 1 more locations
----------------------------------------

57. An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours
   NCT ID: NCT02236910
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Neuroendocrine Carcinoma
   Intervention: Lu-DOTA-TATE
   Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
   Start Date: 2014-07
   Completion Date: 2025-12
   Has Posted Results: False
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02236910
   Summary: Lu-DOTA-TATE (Lutetium-177 octreotate) is a radiopharmaceutical that has been reported as being effective in controlling symptoms and increase quality of life; induce stable disease and extend progression free survival; induce a (good) partial remission and induce a complete remission in patients wi...
   Locations: London Health Sciences Centre, London, Canada
----------------------------------------

58. Real-world Study on Adjuvant Octreotide Therapy in pNETs
   NCT ID: NCT06080204
   Status: COMPLETED
   Phase: NA
   Condition: Pancreatic Neuroendocrine Tumor G2
   Intervention: Octreotide LAR
   Sponsor: Changhai Hospital
   Start Date: 2008-03
   Completion Date: 2020-04
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06080204
   Summary: Adjuvant therapy in pancreatic neuroendocrine tumors (pNETs) after radical resection lacks evidence-based data and is controversial. Real-world data were clustered to validate whether the long-acting octreotide is a potential candidate for adjuvant therapy in high recurrence risk G2 pNET patients.
----------------------------------------

59. Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
   NCT ID: NCT05361668
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Carcinoid Syndrome; Carcinoid; Carcinoid Tumor; Carcinoid Tumor of Ileum; Carcinoid Tumor of Cecum; Carcinoid Syndrome Diarrhea; Carcinoid Intestine Tumor; Carcinoid Tumor of Liver; Carcinoid Tumor of Pancreas
   Intervention: Randomized: 40 mg Paltusotine; Randomized: 80 mg Paltusotine
   Sponsor: Crinetics Pharmaceuticals Inc.
   Start Date: 2022-06-17
   Completion Date: 2026-02
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05361668
   Summary: The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome. This study consists of a Randomized Treatment Phase followed by an Open-Label Extension (OLE) Phase.
   Locations: Crinetics Study Site, Los Angeles, United States; Crinetics Study Site, Los Angeles, United States; Crinetics Study Site, Newport Beach, United States
              ... and 32 more locations
----------------------------------------

60. Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms
   NCT ID: NCT03834701
   Status: COMPLETED
   Phase: NA
   Condition: Neuroendocrine Tumors; Neuroendocrine Carcinoma; Pancreas Neoplasm; Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting
   Intervention: EUS guided radiofrequency ablation
   Sponsor: Catholic University of the Sacred Heart
   Start Date: 2019-09-01
   Completion Date: 2024-02-01
   Has Posted Results: False
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03834701
   Summary: This study evaluates the possibility and the safety of performing local therapy for Pancreatic neuroendocrine neoplasms (PanNENs) using radiofrequency ablation of the tumor under ultrasonography (EUS) guidance.
   Locations: Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy; Universita' del Sacro Cuore, Rome, Italy
----------------------------------------

61. 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
   NCT ID: NCT03042416
   Status: COMPLETED
   Phase: PHASE3
   Condition: Congenital Hyperinsulinism; Neuroblastoma; Neuroendocrine Tumors; Parkinson Disease; Brain Glioma
   Intervention: 18F-DOPA
   Sponsor: University of Alberta
   Start Date: 2017-06-29
   Completion Date: 2021-06-02
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03042416
   Summary: Single centre prospective cohort phase III study of 18F-DOPA PET/CT imaging in specific patient populations:

1. Pediatric patients with congenital hyperinsulinism
2. Pediatric patients with neuroblastoma
3. Pediatric or Adult patients with suspected extra-pancreatic neuroendocrine tumor
4. Adult pa...
   Locations: University of Alberta Hospital, Edmonton, Canada
----------------------------------------

62. A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
   NCT ID: NCT02923934
   Status: COMPLETED
   Phase: PHASE2
   Condition: Gastrointestinal Cancer; Neuroendocrine Tumours; Malignant Female Reproductive System Neoplasm
   Intervention: Ipilimumab; Nivolumab
   Sponsor: Olivia Newton-John Cancer Research Institute
   Start Date: 2017-08-22
   Completion Date: 2023-12-12
   Has Posted Results: False
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02923934
   Summary: The three tumour streams that will be studied in this protocol are: (i) upper GI malignancies (comprising intra-hepatic/extra-hepatic cholangiocarcinomas,gall bladder cancers and duodenal cancers).); (ii) neuroendocrine tumours (inc. Pancreatic, bronchial and intestinal carcinoid tumours) and (iii) ...
   Locations: Border Medical Oncology Unit, Albury, Australia; Blacktown Hospital, Sydney, Australia; Monash Health, Clayton, Australia
              ... and 2 more locations
----------------------------------------

63. Exploration of Molecular Biomarkers for Lu-177 DOTATATE Therapy in Midgut Neuroendocrine Tumor
   NCT ID: NCT03667092
   Status: COMPLETED
   Phase: NA
   Condition: Midgut Neuroendocrine Tumors
   Intervention: non-drug intervention type
   Sponsor: University Hospital, Toulouse
   Start Date: 2018-09-01
   Completion Date: 2024-05-22
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03667092
   Summary: Midgut neuroendocrine tumours present an increasing incidence and poor survival at 5 years with limited therapeutic options for metastatic, non-operable cases. Lu-177 Dotatate, targeting somatostatin receptors, is an internal vectorized radiotherapy using Lu-177, an ideal radionuclide for peptide ra...
   Locations: CHU de Toulouse, Toulouse, France
----------------------------------------

64. Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
   NCT ID: NCT04079712
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Metastatic Large Cell Neuroendocrine Carcinoma; Metastatic Neuroendocrine Carcinoma; Metastatic Neuroendocrine Neoplasm; Metastatic Small Cell Neuroendocrine Carcinoma
   Intervention: Cabozantinib S-malate; Ipilimumab; Nivolumab
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2020-08-06
   Completion Date: 2026-07-14
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04079712
   Summary: This phase II trial studies how well the combination of XL184 (cabozantinib), nivolumab, and ipilimumab work in treating patients with poorly differentiated neuroendocrine tumors (i.e., neuroendocrine tumor that does not look like the normal tissue it arose from). Cabozantinib may stop the growth of...
   Locations: University of Alabama at Birmingham Cancer Center, Birmingham, United States; Banner University Medical Center - Tucson, Tucson, United States; University of Arizona Cancer Center-North Campus, Tucson, United States
              ... and 43 more locations
----------------------------------------

65. Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors
   NCT ID: NCT03498040
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Condition: Carcinoid Heart Disease
   Intervention: Study of the occurrence of Carcinoid Heart Disease
   Sponsor: Hospices Civils de Lyon
   Start Date: 2018-04-16
   Completion Date: 2033-04-16
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03498040
   Summary: Carcinoid Heart Disease (CHD) is a rare form of heart disease, occurring in over 50% of the patients with carcinoid syndrome. Pathophysiology, prognostic factors of development of Carcinoid Heart Disease and progression of disease remain unclear.

This observational multicenter cohort study is desig...
   Locations: CHU Amiens, Amiens, France; CHU Angers, Angers, France; CHU Bordeaux - Hopital Haut-Lévèque, Bordeaux, France
              ... and 16 more locations
----------------------------------------

66. Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
   NCT ID: NCT02595424
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Gastric Neuroendocrine Carcinoma; Intestinal Neuroendocrine Carcinoma; Pancreatic Neuroendocrine Carcinoma
   Intervention: Capecitabine; Carboplatin; Cisplatin; Etoposide; Laboratory Biomarker Analysis; Temozolomide
   Sponsor: ECOG-ACRIN Cancer Research Group
   Start Date: 2016-04-06
   Completion Date: 2029-01-01
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02595424
   Summary: This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin or carboplatin and etoposide in treating patients with neuroendocrine carcinoma of the gastrointestinal tract or pancreas that has spread to other parts of the body (metas...
   Locations: Kingman Regional Medical Center, Kingman, United States; Cancer Center at Saint Joseph's, Phoenix, United States; Mercy Hospital Fort Smith, Fort Smith, United States
              ... and 670 more locations
----------------------------------------

67. Prospective Evaluation of a Program for Early Identification of Needs and Multidisciplinary Intervention in Supportive Care in Digestive Oncology
   NCT ID: NCT04478175
   Status: COMPLETED
   Phase: NA
   Condition: Non-colorectal Cancer (Esophagus, Stomach, Liver/Bile Ducts, Pancreas, Neuroendocrine Carcinoma); Colorectal With Associated Risk Factors
   Intervention: multidisciplinary assessment and intervention
   Sponsor: Institut Curie
   Start Date: 2021-04-29
   Completion Date: 2022-10-05
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04478175
   Summary: Patients with advanced gastrointestinal (GI) cancers are very often sarcopenic/malnourished at diagnosis (\> 60% of cases) and at high risk of rapid clinical deterioration. These patients have important supportive care needs that represent a major challenge for improving treatment tolerance and pati...
   Locations: Institut Curie, Paris, France
----------------------------------------

68. LUTATHERA Injection General Use Result Survey
   NCT ID: NCT05844332
   Status: COMPLETED
   Phase: N/A
   Condition: Somatostatin Receptor-positive Neuroendocrine Tumor
   Intervention: LUTATHERA
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2021-12-17
   Completion Date: 2024-06-27
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05844332
   Summary: This study is a multicenter observational study with a central registration system and all-case surveillance system without a control group.
   Locations: Novartis Investigative Site, Nagoya, Japan; Novartis Investigative Site, Hirosaki, Japan; Novartis Investigative Site, Kamogawa, Japan
              ... and 43 more locations
----------------------------------------

69. Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
   NCT ID: NCT04291885
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Merkel Cell Carcinoma; Merkel Cell Carcinoma, Stage I; Merkel Cell Carcinoma, Stage II; Merkel Cell Carcinoma, Stage III; Neuroendocrine Tumors; Carcinoma Neuroendocrine Skin
   Intervention: Avelumab; Placebo
   Sponsor: Melanoma and Skin Cancer Trials Limited
   Start Date: 2020-10-26
   Completion Date: 2030-04-30
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04291885
   Summary: The I-MAT trial is a randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma aiming to explore the efficacy of avelumab as adjuvant immunotherapy.
   Locations: Port Macquarie Base Hospital, Port Macquarie, Australia; Chris O'Brien Lifehouse, Sydney, Australia; Melanoma Institute Australia, Sydney, Australia
              ... and 17 more locations
----------------------------------------

70. Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
   NCT ID: NCT03110978
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Lung Atypical Carcinoid Tumor; Lung Neuroendocrine Neoplasm; Lung Non-Small Cell Squamous Carcinoma; Minimally Invasive Lung Adenocarcinoma; Neuroendocrine Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Lung Large Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8
   Intervention: Nivolumab; Stereotactic Body Radiation Therapy
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2017-06-26
   Completion Date: 2026-06-30
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03110978
   Summary: This phase II trial studies how well stereotactic body radiation therapy with or without nivolumab works in treating patients with stage I-IIA non-small cell lung cancer or cancer that has come back. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiati...
   Locations: MD Anderson in The Woodlands, Conroe, United States; M D Anderson Cancer Center, Houston, United States; MD Anderson West Houston, Houston, United States
----------------------------------------

71. Correlation Between Body Composition and Pathologic Grade/Prognosis in GEP-NENs: A Retrospective Study
   NCT ID: NCT06983106
   Status: COMPLETED
   Phase: N/A
   Condition: Neuroendocrine Tumors
   Intervention: body composition calculate
   Sponsor: Tongji Hospital
   Start Date: 2024-11-04
   Completion Date: 2025-03-29
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06983106
   Summary: The goal of this observational study is to learn about the value of body composition as predictors of pathological grading and prognosis in patients with gastroenteropancreatic neuroendocrine neoplasms.

The main question it aims to answer is: Does body composition affect the pathological grading an...
   Locations: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
----------------------------------------

72. Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs
   NCT ID: NCT04696042
   Status: COMPLETED
   Phase: N/A
   Condition: Neuroendocrine Tumors
   Intervention: Lanreotide autogel
   Sponsor: Asan Medical Center
   Start Date: 2021-01-01
   Completion Date: 2025-01-27
   Has Posted Results: False
   Publications Count: 5
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04696042
   Summary: Lanreotide Autogel® has been established as a standard of care for patients with locally advanced or metastatic GEP-NETs based on the success of CLARINET trial. However, only few patients with Asian ethnicity were included in the trial.

According to the nationwide comprehensive study of patients wi...
   Locations: Changhoon Yoo, Seoul, Korea, Republic of
----------------------------------------

73. Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
   NCT ID: NCT03870399
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Progesterone Receptor Positive Tumor; Estrogen Receptor Positive Tumor
   Intervention: Tamoxifen
   Sponsor: AC Camargo Cancer Center
   Start Date: 2019-03-13
   Completion Date: 2023-05-13
   Has Posted Results: False
   Publications Count: 21
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03870399
   Summary: This is a single-arm, unicentric, single-stage clinical study of tamoxifen for patients with well differentiated neuroendocrine tumors and radiological progression with positive (\> 1 percent) HR (estrogen and / or progesterone) expression by IHC. It will evaluate if Tamoxifen exerts antitumor actio...
   Locations: H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States; AC Camargo Cancer Center, São Paulo, Brazil
----------------------------------------

74. Assessment of What Patients and Healthcare Providers Value
   NCT ID: NCT04483349
   Status: COMPLETED
   Phase: N/A
   Condition: Gastric Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Neuroendocrine Carcinoma
   Intervention: Survey Administration
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2020-06-11
   Completion Date: 2022-08-11
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04483349
   Summary: To assess the importance patients place on each of the attributes of value (i.e., outcomes, quality of life \[QOL\], cost, experience), and how these patientsâ€™ views differ depending on the stage of their therapy (pretreatment, preoperative therapy, post-operative, long-term surveillance, recurren...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

75. Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
   NCT ID: NCT03074513
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Appendix Adenocarcinoma; Human Papillomavirus-Related Anal Squamous Cell Carcinoma; Human Papillomavirus-Related Cervical Squamous Cell Carcinoma; Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis; Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma; Neuroendocrine Carcinoma; Pancreatic Neuroendocrine Tumor; Recurrent Merkel Cell Carcinoma; Recurrent Nasopharynx Carcinoma; Recurrent Peritoneal Malignant Mesothelioma; Recurrent Pleural Malignant Mesothelioma; Stage III Merkel Cell Carcinoma AJCC v7; Stage III Nasopharyngeal Carcinoma AJCC v7; Stage III Pleural Malignant Mesothelioma AJCC v7; Stage IV Merkel Cell Carcinoma AJCC v7; Stage IV Nasopharyngeal Carcinoma AJCC v7; Stage IV Pleural Malignant Mesothelioma AJCC v7; Stage IVA Nasopharyngeal Carcinoma AJCC v7; Stage IVB Nasopharyngeal Carcinoma AJCC v7; Stage IVC Nasopharyngeal Carcinoma AJCC v7; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
   Intervention: Atezolizumab; Bevacizumab; Laboratory Biomarker Analysis; Pharmacological Study
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2017-03-03
   Completion Date: 2025-09-30
   Has Posted Results: False
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03074513
   Summary: This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells t...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

76. A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan
   NCT ID: NCT06240741
   Status: COMPLETED
   Phase: PHASE3
   Condition: Neuroendocrine Neoplasms
   Intervention: [68Ga]Ga-DOTA-TATE; 68Ge/68Ga Generator
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2024-03-21
   Completion Date: 2024-12-27
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06240741
   Summary: The purpose of this study is to evaluate the diagnostic performance of \[68Ga\]Ga-DOTA-TATE Positron Emission Tomography (PET)/Computerized Tomography (CT) imaging compared with conventional imaging (CIM) as standard of truth in patients with neuroendocrine neoplasms (NENs) and healthy volunteers (H...
   Locations: Novartis Investigative Site, Kashiwa, Japan; Novartis Investigative Site, Fukuoka city, Japan; Novartis Investigative Site, Sapporo city, Japan
              ... and 5 more locations
----------------------------------------

77. Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma
   NCT ID: NCT04705519
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Carcinoma
   Intervention: Nab-paclitaxel Combined With Bevacizumab
   Sponsor: Peking University
   Start Date: 2021-01-05
   Completion Date: 2024-09-30
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04705519
   Summary: This is an open-label, phase II study evaluating efficacy and safety of Nab-paclitaxel Combined With Bevacizumab for unresectable Recurrent or metastatic extrapulmonary neuroendocrine carcinoma.
   Locations: Beijing Cancer Hospital, Beijing, China
----------------------------------------

78. SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors
   NCT ID: NCT02840149
   Status: COMPLETED
   Phase: PHASE3
   Condition: Neuroendocrine Tumors
   Intervention: 68Ga-DOTATATE PET/CT
   Sponsor: Jewish General Hospital
   Start Date: 2019-10-01
   Completion Date: 2023-12-13
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02840149
   Summary: Positron emission tomography/computed tomography (PET/CT) is an advanced nuclear medicine scan. This technology allows precise and early cancer to be visualized and measured on whole body images. Patients with Neuro-Endocrine tumors (NETs), require specialized molecular imaging to stage, re-stage an...
   Locations: Jewish General Hospital, Montréal, Canada
----------------------------------------

79. Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
   NCT ID: NCT03335670
   Status: ACTIVE_NOT_RECRUITING
   Phase: EARLY_PHASE1
   Condition: Neuroendocrine Tumors
   Intervention: [68Ga]Pentixafor
   Sponsor: Yusuf Menda
   Start Date: 2017-11-03
   Completion Date: 2030-06-30
   Has Posted Results: False
   Publications Count: 3
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03335670
   Summary: This study will evaluate how Gallium-68 Pentixafor is distributed in neuroendocrine tumor patients and if that distribution is consistent through repeated scans. This is an RDRC study - as such, the images obtained for this study cannot be used clinically or shared with treating oncologists.
   Locations: Holden Comprehensive Cancer Center, Iowa City, United States
----------------------------------------

80. Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors
   NCT ID: NCT02838342
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors
   Intervention: Metronomic cyclophosphamide; Interferon-alpha
   Sponsor: Centre Hospitalier Universitaire de Besancon
   Start Date: 2015-05-19
   Completion Date: 2021-06-29
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02838342
   Summary: This study will evaluate the potential immunomodulatory synergy of the association of metronomic cyclophosphamide (CMC) and interferon-alpha (IFN-alpha).
   Locations: Centre Hospitalier Universitaire de Besançon, Besancon, France; Hôpital Nord Franche-Comté, Montbéliard, France
----------------------------------------

81. A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET
   NCT ID: NCT05050942
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Condition: Gastro-enteropancreatic Neuroendocrine Tumor
   Intervention: CAM2029; Octreotide LAR; Lanreotide ATG
   Sponsor: Camurus AB
   Start Date: 2021-10-22
   Completion Date: 2027-12
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05050942
   Summary: The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with...
   Locations: Mayo Clinic Cancer Center (MCCC) - Phoenix, Phoenix, United States; UCLA Ahmanson Biological Imaging Center, Santa Monica, United States; Rocky Mountain Cancer Centers - Denver - Midtown, Denver, United States
              ... and 95 more locations
----------------------------------------

82. Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
   NCT ID: NCT04848337
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Prostate Cancer Metastatic; Neuroendocrine Tumors
   Intervention: Pembrolizumab; Lenvatinib
   Sponsor: University of Michigan Rogel Cancer Center
   Start Date: 2021-05-25
   Completion Date: 2025-12
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04848337
   Summary: Eligible patients will be treated with the combination of lenvatinib and pembrolizumab. A cycle equals 21 days and therapy will continue until radiographic progression, intolerable toxicity, or patient/physician wishes to discontinue protocol therapy. A maximum of 35 cycles may be administered. On D...
   Locations: City of Hope, Duarte, United States; Winship Cancer Instituted of Emory University, Atlanta, United States; University of Michigan Health System, Ann Arbor, United States
              ... and 2 more locations
----------------------------------------

83. 68Ga-DOTATATE PET for Management of Neuroendocrine Tumors
   NCT ID: NCT03873870
   Status: COMPLETED
   Phase: NA
   Condition: Neuroendocrine Tumors
   Intervention: 68Ga -DOTATATE PET scans
   Sponsor: University Health Network, Toronto
   Start Date: 2019-03-28
   Completion Date: 2023-04-30
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03873870
   Summary: This is a research study to collect information regarding usefulness of positron emission tomography (PET) scans using a special dye called 68Ga-DOTATATE for patients with neuroendocrine tumours by determining the number of of patients whose clinical management was changed as a result of the scans.
   Locations: Princess Margaret Cancer Centre, Toronto, Canada
----------------------------------------

84. Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study
   NCT ID: NCT02113800
   Status: COMPLETED
   Phase: PHASE2
   Condition: Poorly Differentiated Malignant Neuroendocrine Carcinoma; Neuroendocrine Carcinoma, Grade 3; Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3; Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3; Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)
   Intervention: Everolimus (Afinitor®)
   Sponsor: AIO-Studien-gGmbH
   Start Date: 2015-08
   Completion Date: 2020-04
   Has Posted Results: False
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02113800
   Summary: The study is designed as an open-label, prospective, single arm, multicenter study of everolimus in histologically confirmed, neuroendocrine carcinoma G3 /neuroendocrine tumor G3 after failure of first-line platin-based chemotherapy (open-label pilot study).

The aim of this study is to provide a se...
   Locations: Charité-Universitätsmedizin, Medizinische Klinik m. S. Hepatologie und Gastroenterologie, Campus Virchow-Klinikum, Berlin, Germany
----------------------------------------

85. ML Decision Model for G-NEC Adjuvant Therapy
   NCT ID: NCT06663852
   Status: COMPLETED
   Phase: N/A
   Condition: Gastric Neuroendocrine Carcinoma (G-NEC); Postoperative Adjuvant Therapy for G-NEC; Survival Outcomes; Machine Learning
   Intervention: 
   Sponsor: Chang-Ming Huang, Prof.
   Start Date: 2024-01-01
   Completion Date: 2024-06-30
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06663852
   Summary: Gastric neuroendocrine carcinoma (G-NEC) is a rare and aggressive tumor originating from neuroendocrine cells in the stomach lining. It is characterized by a high propensity for recurrence and a generally poor prognosis. Due to its rarity, there is limited data and no established consensus on the op...
   Locations: Fujian Medical University, Fuzhou, China
----------------------------------------

86. Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors
   NCT ID: NCT02810600
   Status: COMPLETED
   Phase: N/A
   Condition: Neuroendocrine Tumors
   Intervention: Gallium-68 DOTA TATE PET scan
   Sponsor: Centre de recherche du Centre hospitalier universitaire de Sherbrooke
   Start Date: 2016-06-08
   Completion Date: 2020-05-29
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02810600
   Summary: Phase-II, prospective, open label, no control group to assess the safety of 68Ga-DOTA-TATE injection in patients with suspected or diagnosed with tumors expressing somatostatin receptors. Each included patient will receive an administered dose of 50 mcg or less of the peptide (DOTA-TATE) and a range...
   Locations: Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Canada
----------------------------------------

87. PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105
   NCT ID: NCT03278275
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors
   Intervention: One injection of 68Ga-NOTA-AE105; PET/CT
   Sponsor: Rigshospitalet, Denmark
   Start Date: 2017-11-01
   Completion Date: 2021-07-08
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03278275
   Summary: The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of uPAR PET/CT with the radioligand 68Ga-NOTA-AE105 in patients with neuroendocrine tumors (NETs).
   Locations: Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, Denmark
----------------------------------------

88. Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
   NCT ID: NCT04592237
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Small Cell Carcinoma; Stage IV Prostate Cancer AJCC v8
   Intervention: Cabazitaxel; Carboplatin; Cetrelimab; Niraparib
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2020-12-29
   Completion Date: 2025-12-31
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04592237
   Summary: This phase II trial studies the effect of cabazitaxel, carboplatin, and cetrelimab followed by niraparib with or without cetrelimab in treating patients with aggressive variant prostate cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as cabazitaxel and carbo...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

89. Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
   NCT ID: NCT04869137
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Merkel Cell Carcinoma; Neuroendocrine Carcinoma of the Skin; Trabecular Carcinoma of the Skin
   Intervention: Lenvatinib Oral Product; Pembrolizumab
   Sponsor: H. Lee Moffitt Cancer Center and Research Institute
   Start Date: 2021-05-28
   Completion Date: 2026-09
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04869137
   Summary: This is a single arm trial of participants with Merkel cell carcinoma receiving a combination of lenvatinib plus pembrolizumab.
   Locations: Moffitt Cancer Center, Tampa, United States
----------------------------------------

90. The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
   NCT ID: NCT01423734
   Status: COMPLETED
   Phase: N/A
   Condition: Gastro-enteropancreatic Neuroendocrine Tumor; Secondary Malignant Neoplasm of Liver
   Intervention: magnetic resonance imaging (MRI)
   Sponsor: Memorial Sloan Kettering Cancer Center
   Start Date: 2011-08-23
   Completion Date: 2023-01-19
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01423734
   Summary: Imaging with CT (Computed Tomography) or MRI (Magnetic Resonance Imaging) is normally used to see how tumors respond to treatment. If tumors shrink after therapy, doctors continue with the same treatment. On the other hand, growing tumors in a patient can bring about a change in therapy. Unfortunate...
   Locations: Memorial Sloan Kettering Cancer Center, New York, United States
----------------------------------------

91. A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
   NCT ID: NCT06148636
   Status: ACTIVE_NOT_RECRUITING
   Phase: EARLY_PHASE1
   Condition: Neuroendocrine Tumors; Neuroendocrine Tumor of the Lung; Neuroendocrine Tumor Grade 1; Neuroendocrine Tumor Grade 2; Neuroendocrine Tumor of Pancreas
   Intervention: [212Pb] VMT-α-NET; [203Pb] VMT-α-NET SPECT/CT
   Sponsor: David Bushnell
   Start Date: 2023-11-10
   Completion Date: 2027-11-20
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06148636
   Summary: This is a safety study to determine the recommended dose to test in clinical trials. The study involves two treatments with 212Pb (212-lead) VMT-α-NET. This is a safety study only; it will most likely not provide therapeutic benefit.
   Locations: Holden Comprehensive Cancer Center at the University of Iowa, Iowa City, United States
----------------------------------------

92. Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors
   NCT ID: NCT04804371
   Status: ACTIVE_NOT_RECRUITING
   Phase: NA
   Condition: Neuroendocrine Tumors
   Intervention: F18-FDG
   Sponsor: University Health Network, Toronto
   Start Date: 2021-03-04
   Completion Date: 2026-02-22
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04804371
   Summary: The variable clinical outcome of patients with G2 \& G3 well diff GEP-NETs makes the selection of an optimal treatment strategy challenging.

Initial data suggests that high DOTATATE uptake and low FDG uptake are suggestive of low grade disease, with an indolent course.

Conversely, low DT uptake an...
   Locations: Princess Margaret Cancer Centre, Toronto, Canada
----------------------------------------

93. Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma
   NCT ID: NCT03022188
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Condition: Neuroendocrine Tumors
   Intervention: 
   Sponsor: Société Française d'Endoscopie Digestive
   Start Date: 2017-01-10
   Completion Date: 2026-12
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03022188
   Summary: Neuroendocrine tumors (NETs) and carcinomas account for 10-15 % of all pancreatic incidentalomas. The management of pancreatic NETs depends on tumor stage and on presence or not of hormonal syndrome. The therapeutic approach for hormonally functional tumor, or large tumor (\> 2 cm) with local, vascu...
   Locations: Clinique Universitaire Saint Luc, Louvain, Belgium; Hopital Sud, Amiens, France; CHU Angers, Angers, France
              ... and 19 more locations
----------------------------------------

94. Artificial Intelligence in EUS for Diagnosing Pancreatic Solid Lesions
   NCT ID: NCT05476978
   Status: COMPLETED
   Phase: N/A
   Condition: Pancreatic Ductal Adenocarcinoma; Pancreatitis, Chronic; Pancreatic Neuroendocrine Tumor; Autoimmune Pancreatitis
   Intervention: EUS-AI model
   Sponsor: Huazhong University of Science and Technology
   Start Date: 2022-07-01
   Completion Date: 2024-01-24
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05476978
   Summary: We aim to develop an EUS-AI model which can facilitate clinical diagnosis by analyzing EUS pictures and clinical parameters of patients.
   Locations: Tongji hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
----------------------------------------

95. Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
   NCT ID: NCT03950609
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Advanced Carcinoid Tumor; Digestive System Neuroendocrine Neoplasm; Multiple Endocrine Neoplasia Type 1; Neuroendocrine Neoplasm; Unresectable Carcinoid Tumor
   Intervention: Everolimus; Lenvatinib
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2019-07-30
   Completion Date: 2026-03-30
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03950609
   Summary: This phase II trial studies how well lenvatinib and everolimus work in treating patients with carcinoid tumors that have spread to other places in the body (advanced) and cannot be removed by surgery (unresectable). Lenvatinib and everolimus may stop the growth of tumor cells by blocking some of the...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

96. Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
   NCT ID: NCT04701307
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Lung Small Cell Carcinoma; Neuroendocrine Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8
   Intervention: Dostarlimab; Niraparib
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2021-02-01
   Completion Date: 2025-11-30
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04701307
   Summary: This phase II trial studies the effect of niraparib and dostarlimab in treating small cell lung cancer and other high-grade neuroendocrine carcinomas. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cance...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

97. Efficacy of Endoscopic Band Ligation (DEBL) for Duodenal Neuroendocrine Neoplasms(dNENs)
   NCT ID: NCT06790056
   Status: COMPLETED
   Phase: N/A
   Condition: Duodenal Neuroendocrine Tumor
   Intervention: duodenal ndoscopic bind ligation
   Sponsor: Asian Institute of Gastroenterology, India
   Start Date: 2024-02-29
   Completion Date: 2024-11-11
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06790056
   Summary: Primary objective To evaluate the therapeutic efficacy (clinical success) of dEBL at 3 months

2b. Secondary objective

To evaluate adverse events, technical success and recurrence on follow-up

50 patients over 1-year duration based on our previous study of Prospective data (2023-2024)
   Locations: Hardik Rughwani, Hyderabad, India
----------------------------------------

98. Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs
   NCT ID: NCT03722511
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Carcinoid Tumor of GI System; Diarrhea; Carcinoid Syndrome
   Intervention: Amino Acid Based Medical Food/Drink
   Sponsor: Lowell Anthony, MD
   Start Date: 2018-12-06
   Completion Date: 2021-05-18
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03722511
   Summary: Primary Objective:

To assess how an amino acid based medical food (Enterade®) helps maintain the intestine's ability to absorb and retain fluids, leading to a reduction in diarrhea due to Neuroendocrine Tumors (NET) and/or Carcinoid Syndrome. This improvement in the absorption will be assessed in p...
   Locations: University of Kentucky Markey Cancer Center, Lexington, United States
----------------------------------------

99. Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan
   NCT ID: NCT02102893
   Status: COMPLETED
   Phase: N/A
   Condition: Neuroendocrine Tumors
   Intervention: 
   Sponsor: National Health Research Institutes, Taiwan
   Start Date: 2014-02-13
   Completion Date: 2020-04-15
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02102893
   Summary: Neuroendocrine tumors (NETs) are neoplasms originating from neuroendocrine cells located throughout the body. They secret various peptides and cause various symptoms (carcinoid syndrome) or not. The incidence of NETs was not well-known till recently when Yao et al. and Hausa et al. published their s...
   Locations: Changhua Christian Hospital, Changhua, Taiwan; Chang-Gung Memorial Hospital, Taipei, Taiwan; National Taiwan University Hospital, Taipei, Taiwan
----------------------------------------

100. Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors
   NCT ID: NCT04510311
   Status: COMPLETED
   Phase: EARLY_PHASE1
   Condition: Neuroendocrine Tumors
   Intervention: 3-[18F]Fluoro-para-hydroxyphenethylguanidine; [123I] metaiodobenzylguanidine; Positron emission tomography/computed tomography scan; Planar scintigraphy scan; Single photon emission computed tomography/computed tomography scan
   Sponsor: University of Michigan Rogel Cancer Center
   Start Date: 2020-10-19
   Completion Date: 2024-12-31
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04510311
   Summary: The goal of this exploratory study is to test whether \[18F\]3F-PHPG can be used reliably to map the locations of tumors in patients with neuroendocrine tumors. If so, the results of this study will be used to support further development of \[18F\]3F-PHPG as a clinical tool for neuroendocrine tumor ...
   Locations: University of Michigan Rogel Cancer Center, Ann Arbor, United States
----------------------------------------

101. Distant Metastases and Long-Term Survival After Complete Resection of Neuroendocrine Tumors of the Appendix
   NCT ID: NCT03852693
   Status: COMPLETED
   Phase: N/A
   Condition: Neuroendocrine Tumors of the Appendix
   Intervention: Histopathological review
   Sponsor: Insel Gruppe AG, University Hospital Bern
   Start Date: 2020-10-01
   Completion Date: 2022-08-30
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03852693
   Summary: The aim of the present project is to evaluate the frequency of distant metastases and clinically relevant relapse and mortality, respectively, of aNEN (Neuroendocrine Neoplasms of the Appendix) measuring 1 - 2 cm.

The investigators hypothesize that the mortality rate of aNET (Neuroendocrine Tumors ...
   Locations: UHIBerne, Bern, Switzerland
----------------------------------------

102. A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent
   NCT ID: NCT05111509
   Status: ACTIVE_NOT_RECRUITING
   Phase: EARLY_PHASE1
   Condition: Neuroendocrine Tumor Grade 2; Neuroendocrine Tumor Grade 1
   Intervention: [203Pb]VMT-α-NET; SPECT/CT
   Sponsor: Yusuf Menda
   Start Date: 2022-08-22
   Completion Date: 2026-06-30
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05111509
   Summary: This is a first in man study to determine if \[203Pb\]VMT-α-NET identifies neuroendocrine tumors with SPECT/CT. This is the first step to testing \[212Pb\]-based alpha radiation therapy in neuroendocrine therapy.
   Locations: The University of Iowa, Iowa City, United States
----------------------------------------

103. Clinical Relevance of the Salvage Treatment for Colorectal Neuroendocrine Tumors
   NCT ID: NCT06143605
   Status: COMPLETED
   Phase: N/A
   Condition: Rectal Neoplasms; Neuroendocrine Tumors
   Intervention: salvage treatment
   Sponsor: Yanhong Deng
   Start Date: 2013-01-30
   Completion Date: 2023-09-30
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06143605
   Summary: we evaluated all related clinical and pathologic data of rectal NET cases, including the resection margin status, NET grading, and lymphovascular invasion status. Finally, the present study was aimed at (1) determining the risk factors for LN and distant metastases in colorectal NETs (2) clarifying ...
----------------------------------------

104. Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
   NCT ID: NCT05247905
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Metastatic Pancreatic Neuroendocrine Tumor; Unresectable Pancreatic Neuroendocrine Carcinoma
   Intervention: Lutetium Lu 177 Dotatate; Capecitabine; Temozolomide; Quality-of-Life Assessment; Questionnaire Administration
   Sponsor: Alliance for Clinical Trials in Oncology
   Start Date: 2023-02-16
   Completion Date: 2033-10-01
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05247905
   Summary: This phase II trial compares capecitabine and temozolomide to lutetium Lu 177 dotatate for the treatment of pancreatic neuroendocrine tumors that have spread to other parts of the body (advanced) or are not able to be removed by surgery (unresectable). Chemotherapy drugs, such as capecitabine and te...
   Locations: Fairbanks Memorial Hospital, Fairbanks, United States; Mayo Clinic Hospital in Arizona, Phoenix, United States; Tower Cancer Research Foundation, Beverly Hills, United States
              ... and 168 more locations
----------------------------------------

105. Personalized PRRT of Neuroendocrine Tumors
   NCT ID: NCT02754297
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Carcinoid Tumor; Carcinoma, Neuroendocrine
   Intervention: 177Lu-Octreotate
   Sponsor: CHU de Quebec-Universite Laval
   Start Date: 2016-04-12
   Completion Date: 2029-04-12
   Has Posted Results: False
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02754297
   Summary: In this study, peptide receptor radionuclide therapy (PRRT) with 177Lu-Octreotate (LuTate) will be personalized, i.e. administered activity of LuTate will be tailored for each patient to maximize absorbed radiation dose to tumor, while limiting that to healthy organs.

The purpose of this study is t...
   Locations: CHU de Québec - Université Laval, Quebec City, Canada
----------------------------------------

106. Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
   NCT ID: NCT03728361
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Grade I Neuroendocrine Carcinoma; Grade II Neuroendocrine Carcinoma; Grade III Neuroendocrine Carcinoma; Metastatic Neuroendocrine Carcinoma; Neuroendocrine Carcinoma; Recurrent Small Cell Lung Carcinoma; Refractory Small Cell Lung Carcinoma; Lung Cancer Stage IV; Large Cell Neuroendocrine Carcinoma; Neuroendocrine Tumors; Small Cell Lung Cancer Metastatic; Small-cell Lung Cancer
   Intervention: Nivolumab; Temozolomide
   Sponsor: Dwight Owen
   Start Date: 2018-12-31
   Completion Date: 2026-10-31
   Has Posted Results: False
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03728361
   Summary: This phase II trial studies how well nivolumab and temozolomide work in treating patients with small-cell lung cancer that has come back or does not respond to treatment, or neuroendocrine cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as nivolumab...
   Locations: Ohio State University Comprehensive Cancer Center-COHORT 1, Columbus, United States; Ohio State University Comprehensive Cancer Center-COHORT 2, Columbus, United States
----------------------------------------

107. DOTATOC PET/CT for Imaging NET Patients
   NCT ID: NCT03583528
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Condition: Neuroendocrine Tumors; Insulinoma; Gastrinoma; Glucagonoma; Vipoma; Pheochromocytoma; Paraganglioma; Neuroblastoma; Ganglioneuroma; Medullary Carcinoma; Pituitary Adenoma; Medulloblastoma; Merkel Cell Carcinoma; Small-cell Lung Cancer; Meningioma; Carcinoid
   Intervention: 68Ga-DOTATOC PET/CT; 18F-FDG PET/CT
   Sponsor: British Columbia Cancer Agency
   Start Date: 2018-07-11
   Completion Date: 2028-09-30
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03583528
   Summary: Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called somatostatin receptors (SSTR). Somatostatin receptor scintigraphy and conventi...
   Locations: BC Cancer, Vancouver, Canada
----------------------------------------

108. An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
   NCT ID: NCT04993261
   Status: ACTIVE_NOT_RECRUITING
   Phase: EARLY_PHASE1
   Condition: Carcinoid Syndrome; Carcinoid Tumor; Digestive System Neuroendocrine Tumor G1; Metastatic Carcinoid Tumor
   Intervention: Dual-Energy Computed Tomography
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2015-09-23
   Completion Date: 2026-12-31
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04993261
   Summary: This trial studies the use of a special type of computed (CT) scan called dual energy CT in detecting gastrointestinal carcinoid tumors. CT is an imaging technique that uses x-rays and a computer to create images of areas inside the body. Dual energy computed tomography is a technique used during ro...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

109. Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
   NCT ID: NCT04544098
   Status: ACTIVE_NOT_RECRUITING
   Phase: EARLY_PHASE1
   Condition: Neuroendocrine Tumors; Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors
   Intervention: 177Lu-DOTATATE
   Sponsor: Memorial Sloan Kettering Cancer Center
   Start Date: 2020-09-02
   Completion Date: 2026-09
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04544098
   Summary: This study will look at whether it is practical and safe to give Lutathera directly into an artery of the liver (hepatic intraarterial infusion). The researchers will compare the effects of hepatic intraarterial infusion in the liver with the effects of the standard approach (intravenous infusion in...
   Locations: Memorial Sloan Kettering Cancer Center, New York, United States
----------------------------------------

110. Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors
   NCT ID: NCT02826928
   Status: COMPLETED
   Phase: NA
   Condition: Small-intestine Neuroendocrine Tumors (Carcinoid Tumors)
   Intervention: blood sample withdrawn
   Sponsor: CHU de Reims
   Start Date: 2016-10-26
   Completion Date: 2022-06-03
   Has Posted Results: False
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02826928
   Summary: Urinary measure of 5-hydroxyindolacetic acid (5HIAA) is an important marker for the diagnosis and follow-up of patients with small-intestine neuroendocrine tumors. Although this marker has good specificity, its sensitivity is moderate and its dosage is constraining, since it requires urine collectio...
   Locations: Chu Reims, Reims, France
----------------------------------------

111. A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly
   NCT ID: NCT06253897
   Status: COMPLETED
   Phase: N/A
   Condition: Gastro-enteropancreatic Neuroendocrine Tumor; Acromegaly
   Intervention: 
   Sponsor: Ipsen
   Start Date: 2024-05-29
   Completion Date: 2024-12-06
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06253897
   Summary: Participants of this study are adults with GEP-NETs and/or acromegaly who were using the Ipsen lanreotide syringe and have transitioned in the last 6 months to the Pharmathen lanreotide syringe, having received at least two injections using the Pharmathen syringe.

GEP-NETs are abnormal growths that...
   Locations: Pearl IRB, Indianapolis, United States
----------------------------------------

112. MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents
   NCT ID: NCT03217097
   Status: COMPLETED
   Phase: NA
   Condition: Neuroendocrine Tumors
   Intervention: Oxaliplatin-based chemotherapy; Alkylating-based chemotherapy
   Sponsor: Hospices Civils de Lyon
   Start Date: 2018-10-16
   Completion Date: 2022-04-25
   Has Posted Results: False
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03217097
   Summary: Neuroendocrine tumors (NET) are rare but their incidence is growing. Alkylating agents (ALKY) are one of the main systemic treatments used, at least for advanced duodeno-pancreatic NETs, with a response rate of 30 to 40% and a median progression-free survival of 4 to 18 months. Chemotherapy is one o...
   Locations: Hôpital Sud - CHU Amiens, Amiens, France; CHU d'Angers, Angers, France; Hôpital Estaing, CHU de Clermont-Ferrand, Clermont-Ferrand, France
              ... and 16 more locations
----------------------------------------

113. Combination Immunotherapy in Rare Cancers Under InvesTigation
   NCT ID: NCT04969887
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Advanced Biliary Tract Cancer; Neuroendocrine Tumors; Female Reproductive System Neoplasm; MSI-H Solid Malignant Tumor
   Intervention: Ipilimumab; Nivolumab
   Sponsor: Olivia Newton-John Cancer Research Institute
   Start Date: 2021-08-03
   Completion Date: 2028-03
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04969887
   Summary: The four tumour streams that will be studied in this protocol are based on immunotherapy sensitive rare cancers from CA209-538 which will be further investigated under this protocol and divided into four groups:

1. Neuroendocrine cancers: Atypical bronchial carcinoid, neuroendocrine carcinoma and G...
   Locations: Border Medical Oncology Unit, Albury, Australia; Orange Health Service, Orange, Australia; Blacktown Hospital, Sydney, Australia
              ... and 15 more locations
----------------------------------------

114. Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014
   NCT ID: NCT01763554
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Condition: Neuroendocrine Tumors, NET
   Intervention: Lu-177 DOTA-TATE
   Sponsor: AHS Cancer Control Alberta
   Start Date: 2012-08
   Completion Date: 2025-12
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01763554
   Summary: Retrospective review of the medical files of 115 patients with neuroendocrine tumours who were treated with Lutetium-177 DOTA-TATE under Health Canada's Special Access Programme (SAP) at the Cross Cancer Institute between January 2010 and April 30, 2014. Efficacy, safety, and other relevant data wil...
   Locations: Cross Cancer Institute, Edmonton, Canada
----------------------------------------

115. Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs
   NCT ID: NCT02630654
   Status: COMPLETED
   Phase: N/A
   Condition: Gastroenteropancreatic Neuroendocrine Tumors
   Intervention: This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.
   Sponsor: Ipsen
   Start Date: 2014-03-24
   Completion Date: 2021-11-09
   Has Posted Results: False
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02630654
   Summary: This exploratory study aims to evaluate the diagnostic, prognostic and response predictive value of a multi biomarker strategy in patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs) originating from the midgut or pancreas. Using a recently developed methodology enabling the evaluat...
   Locations: North Estonia Medical Center, Tallinn, Estonia; Pauls Stradins Clinical University Hospital, Riga, Latvia; Riga East University Hospital, Riga, Latvia
              ... and 6 more locations
----------------------------------------

116. Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
   NCT ID: NCT03044977
   Status: ACTIVE_NOT_RECRUITING
   Phase: EARLY_PHASE1
   Condition: Neuroendocrine Tumor, Malignant; Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting
   Intervention: 90Y-DOTA-3-Tyr-Octreotide; 131I-MIBG
   Sponsor: David Bushnell
   Start Date: 2017-05-07
   Completion Date: 2027-12
   Has Posted Results: False
   Publications Count: 2
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03044977
   Summary: This study is designed to identify the best tolerated doses of \[131\]Iodine-MIBG and \[90\]Yttrium-DOTATOC when co-administered to treat midgut neuroendocrine tumors. These drugs (131I-MIBG, 90Y-DOTATOC) are radioactive drugs, known as radionuclide therapy. Currently, the safest and best tolerated ...
   Locations: Holden Comprehensive Cancer Center, Iowa City, United States
----------------------------------------

117. Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
   NCT ID: NCT03600233
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Pancreatic Neuroendocrine Tumor; Gastro-enteropancreatic Neuroendocrine Tumor; Lung Neuroendocrine Neoplasm; Neuroendocrine Carcinoma
   Intervention: CVM-1118
   Sponsor: TaiRx, Inc.
   Start Date: 2018-12-15
   Completion Date: 2025-12-31
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03600233
   Summary: CVM-1118 (TRX-818) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objecti...
   Locations: Chang Gung Memorial Hospital, KaoHsiung, Kaohsiung, Taiwan; Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan
              ... and 5 more locations
----------------------------------------

118. Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors
   NCT ID: NCT04552847
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors
   Intervention: Al18F-NOTA-octreotide; PET/CT; PET/MR
   Sponsor: Universitaire Ziekenhuizen KU Leuven
   Start Date: 2020-10-07
   Completion Date: 2022-02-08
   Has Posted Results: False
   Publications Count: 2
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04552847
   Summary: The aim of this study is to evaluate the diagnostic performance of Al18F-NOTA-octreotide PET imaging in comparison with the current golden standard, 68Ga-DOTA-somatostatin analog PET, in neuroendocrine tumor patients.
   Locations: Universitaire Ziekenhuizen Leuven, Leuven, Belgium
----------------------------------------

119. A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients with an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment
   NCT ID: NCT05255133
   Status: COMPLETED
   Phase: NA
   Condition: Neuroendocrine Tumors
   Intervention: Liquid biopsies; Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)
   Sponsor: Universiteit Antwerpen
   Start Date: 2017-10-09
   Completion Date: 2022-06-23
   Has Posted Results: False
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05255133
   Summary: Prospective, multicentric, single arm, POC study to evaluate the value of CtDNA in follow-up of patients treated with everolimus, with or without somatostatin analogues for advanced gastroenteropancreatic or lung neuroendocrine tumours.
   Locations: AZ Rivierenland, Bornem, Belgium; AZ Klina, Brasschaat, Belgium; AZ Monica, Deurne, Belgium
              ... and 5 more locations
----------------------------------------

120. Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer
   NCT ID: NCT02820857
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Carcinomas
   Intervention: Folfiri-bevacizumab; Folfiri
   Sponsor: Hospices Civils de Lyon
   Start Date: 2017-09-04
   Completion Date: 2024-08-24
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02820857
   Summary: Poorly differentiated neuroendocrine carcinomas (NEC) are a sub-group of aggressive neuroendocrine neoplasms (NEN). The most common primary sites are broncho-pulmonary and digestive. The gastroentero-pancreatic NECs (GEP-NEC) represent 7-21% of all of the NENs.

Recent data on the initial presentati...
   Locations: Service d'Hépato-Gastroenterologie et Oncologie Digestive, Hôpital Sud, CHU d'Amiens, Amiens, France; Service d'Hépatogastroentérologie, CHU d'Angers, Angers, France; Service d'Oncologie et Radiothérapie, Institut Sainte Catherine, Avignon, France
              ... and 23 more locations
----------------------------------------

121. A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases
   NCT ID: NCT06853457
   Status: COMPLETED
   Phase: N/A
   Condition: Neuroendocrine Tumors, NET
   Intervention: 
   Sponsor: First Affiliated Hospital, Sun Yat-Sen University
   Start Date: 2014-01-01
   Completion Date: 2024-09-01
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06853457
   Summary: To develop and validate a CT-based transfer learning radiomics model for predicting response to initial TAE in GEP-NETLM patients and compare its performance with traditional radiomics and clinical models.
----------------------------------------

122. Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors
   NCT ID: NCT03454763
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Neuroendocrine Tumors
   Intervention: PRRT every 5 weeks; PRRT every 8-10 weeks
   Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
   Start Date: 2016-05-26
   Completion Date: 2025-01
   Has Posted Results: False
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03454763
   Summary: Randomized Phase II Trial in sstr2 Positive Tumors to Optimize the Interval Between Cycles of PRRT With 177lu-dotatate
   Locations: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
----------------------------------------

123. Preoperative Imaging in Patients With Small Bowel Neuroendocrine Tumors
   NCT ID: NCT05246319
   Status: COMPLETED
   Phase: N/A
   Condition: Neuroendocrine Tumors; Small Intestinal NET; Lymph Node Metastasis
   Intervention: preoperative imaging
   Sponsor: Laurent BRUNAUD
   Start Date: 2012-01-01
   Completion Date: 2025-02-11
   Has Posted Results: False
   Publications Count: 5
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05246319
   Summary: Digestive NETs are the second most common malignant digestive tumor after adenocarcinoma. The most common gastrointestinal NETs arise from the small intestine. These tumors have a high lymph node and distant metastatic potential (hepatic, pulmonary, etc.). Their management is essentially surgical an...
   Locations: CHRU Nancy, Nancy, France; CHRU Nancy - Département Chirurgie Viscérale, Métabolique et Cancérologique CVMC (7ème étage), Nancy, France
----------------------------------------

124. Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases
   NCT ID: NCT03590119
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Liver Metastases
   Intervention: Lutetium Lu 177-DOTATATE
   Sponsor: Marnix Lam
   Start Date: 2018-08-01
   Completion Date: 2022-09-01
   Has Posted Results: False
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03590119
   Summary: The objective is to investigate the impact of intra-arterial administration of 177Lu-dotatate on the intrahepatic biodistribution in patients with NET liver metastases. Our primary objective is to evaluate if there is a difference in post-treatment tumor-to-non-tumor (T/N) activity concentration rat...
   Locations: Antoni van Leeuwenhoek Cancer Institute, Amsterdam, Netherlands; Erasmus MC, Rotterdam, Netherlands; University Medical Center Utrecht, Utrecht, Netherlands
----------------------------------------

125. Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
   NCT ID: NCT02743741
   Status: ACTIVE_NOT_RECRUITING
   Phase: NA
   Condition: Neuroendocrine Tumors
   Intervention: Lutetium-177 Octreotate
   Sponsor: University Health Network, Toronto
   Start Date: 2016-07-15
   Completion Date: 2026-06
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02743741
   Summary: This is a prospective single arm, multicenter study will evaluate the efficacy and safety of Lutetium-177 Octreotate in patients with neuroendocrine tumors who has positive Somatostatin receptor identified by 68Ga-DOTATATE. 195 patients will be enrolled totally. Patient who has progressed with neuro...
   Locations: Juravinski Cancer Centre, Hamilton, Canada; London Health Sciences Centre, London, Canada; Princess Margaret Cancer Centre, Toronto, Canada
              ... and 1 more locations
----------------------------------------

126. Study on Microflora Characteristics of Pancreatic Solid Lesions Via Endoscopic Ultrasound-guided Fine Needle Aspiration/Biopsy
   NCT ID: NCT05171517
   Status: COMPLETED
   Phase: N/A
   Condition: Pancreatic Carcinoma; Pancreatic Neuroendocrine Tumor; Autoimmune Pancreatitis; Microflora
   Intervention: 
   Sponsor: Peking Union Medical College Hospital
   Start Date: 2022-01-01
   Completion Date: 2023-04-30
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05171517
   Summary: Study objective: To describe the microflora characteristics of the pancreatic solid lesions via the tissue acquired via the endoscopic ultrasound-guided fine needle aspiration/biopsy (EUS-FNA/B).

Study design: This is a prospective observational study.
   Locations: Peking Union Medical College Hospital, Beijing, China
----------------------------------------

127. 68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET
   NCT ID: NCT05448157
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Condition: Neuroendocrine Tumor Carcinoid; Neuroendocrine Tumor of Pancreas; Gep Net
   Intervention: 
   Sponsor: European Institute of Oncology
   Start Date: 2022-05-12
   Completion Date: 2023-12-12
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05448157
   Summary: In gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs), radical surgery provides good long-term outcome and low recurrence rates. In GEP-NETs the actual surgical planning is established on the ground of preoperative morphology images (CT scan), and functional imaging using CT/PET with 68Ga-DOT...
   Locations: IRCCS Istituto Europeo di Oncologia S.r.l., Milan, Italy
----------------------------------------

128. Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
   NCT ID: NCT03457948
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Metastatic Malignant Neoplasm in the Liver; Neuroendocrine Neoplasm
   Intervention: Arterial Embolization; Pembrolizumab; Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate; Yttrium-90 Microsphere Radioembolization
   Sponsor: Nicholas Fidelman, MD
   Start Date: 2018-08-27
   Completion Date: 2026-12-31
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03457948
   Summary: This pilot phase II trial studies how effective pembrolizumab and liver-directed therapy or peptide receptor radionuclide therapy are at treating patients with well-differentiated neuroendocrine tumors and symptomatic and/or progressive tumors that have spread to the liver (liver metastases). Immuno...
   Locations: University of California, San Francisco, San Francisco, United States
----------------------------------------

129. Epiction of the Genomic and Genetic Landscape Identifies CCL5 as a Protective Factor in Colorectal Neuroendocrine Carcinoma
   NCT ID: NCT05714722
   Status: COMPLETED
   Phase: N/A
   Condition: Colorectal Neuroendocrine Carcinomas (CRNEC); Genomic Landscape; Genetic Landscape; Prognosis; CCL5; PAX5
   Intervention: 
   Sponsor: Zhejiang University
   Start Date: 2011-01-01
   Completion Date: 2021-01-01
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05714722
   Summary: Background: Colorectal neuroendocrine carcinomas (CRNECs) are highly aggressive tumours with poor prognosis and low incidence. To date, the genomic landscape and molecular pathway alterations have not been elucidated.

Methods: Tissue sections and clinical information were collected as an in-house c...
----------------------------------------

130. Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
   NCT ID: NCT04754425
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Castration-Resistant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents; Metastatic Malignant Neoplasm in the Bone; Metastatic Prostate Adenocarcinoma; Metastatic Prostate Small Cell Neuroendocrine Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
   Intervention: Biopsy; Biospecimen Collection; Erdafitinib
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2021-07-15
   Completion Date: 2026-06-30
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04754425
   Summary: This phase II trial studies the effect of erdafitinib in treating patients with prostate cancer that grows and continues to spread despite the surgical removal of the testes or drugs to block androgen production (castration-resistant). Erdafitinib may stop the growth of tumor cells by blocking some ...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

131. Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly Patients
   NCT ID: NCT06570174
   Status: COMPLETED
   Phase: NA
   Condition: Pancreatic Cancer; Cholangiocarcinoma; Intraductal Papillary Mucinous Neoplasm; Neuroendocrine Tumor; Solid Pseudopapillary Tumor
   Intervention: oral protein supplements; placebo
   Sponsor: Yonsei University
   Start Date: 2021-01-07
   Completion Date: 2022-07-18
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06570174
   Summary: This study investigates the effects of oral protein supplements on the nutritional status and quality of life in elderly patients following standard pancreatic resection. The research aims to determine whether these supplements can improve protein intake and contribute to better skeletal muscle mass...
   Locations: Department of Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of
----------------------------------------

132. 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
   NCT ID: NCT01842165
   Status: COMPLETED
   Phase: PHASE3
   Condition: Gastroenteropancreatic Neuroendocrine Tumors
   Intervention: Intravenous injection of 177Lu-octreotate
   Sponsor: Jules Bordet Institute
   Start Date: 2013-05
   Completion Date: 2022-09-19
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01842165
   Summary: The purpose of this study is to determine if 68Gallium-octreotate and 18Fluorodesoxyglucose uptake, apparent diffusion coefficient and post 177Lu-octreotate SPECT/CT dosimetry are reliable predictors for lesion-by-lesion treatment outcome.
   Locations: Jules Bordet Institute, Brussels, Belgium
----------------------------------------

133. Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
   NCT ID: NCT02834013
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortical Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Breast Metaplastic Carcinoma; Cervical Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Neuroendocrine Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Neoplasm of Unknown Primary; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Solid Neoplasm; Malignant Testicular Sex Cord-Stromal Tumor; Metastatic Pituitary Neuroendocrine Tumor; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Low Grade Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Penile Squamous Cell Carcinoma; Peritoneal Mesothelial Neoplasm; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Spindle Cell Neoplasm; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
   Intervention: Biospecimen Collection; Computed Tomography; Echocardiography Test; Ipilimumab; Magnetic Resonance Imaging; Nivolumab
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2017-01-30
   Completion Date: 2026-05-01
   Has Posted Results: False
   Publications Count: 5
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02834013
   Summary: This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

This tri...
   Locations: University of Alabama at Birmingham Cancer Center, Birmingham, United States; University of South Alabama Mitchell Cancer Institute, Mobile, United States; Anchorage Associates in Radiation Medicine, Anchorage, United States
              ... and 1009 more locations
----------------------------------------

134. Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery
   NCT ID: NCT06204159
   Status: ACTIVE_NOT_RECRUITING
   Phase: NA
   Condition: Hepatocellular Carcinoma; Neuroendocrine Tumors
   Intervention: TACE Catheters
   Sponsor: Abramson Cancer Center at Penn Medicine
   Start Date: 2024-02-01
   Completion Date: 2026-06-30
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06204159
   Summary: The goal of this clinical trial is to compare CT scan of the coverage of tumors treated with TACE using End Hole catheters to those treated with the TriNav catheter that alters tissue pressure. Both catheters are FDA approved for delivery of TACE.

• Is there a difference in CT appearance with deliv...
   Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, United States; University of Pennsylvania, Department of Radiology, Interventional Radiology Division, Philadelphia, United States
----------------------------------------

135. Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study
   NCT ID: NCT02358356
   Status: COMPLETED
   Phase: PHASE2
   Condition: Midgut Neuroendocrine Tumours; Pancreatic Neuroendocrine Tumours
   Intervention: octreotate; Capecitabine; Temozolomide
   Sponsor: Australasian Gastro-Intestinal Trials Group
   Start Date: 2015-11
   Completion Date: 2021-10-31
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02358356
   Summary: Two parallel phase II randomized open label trials of Lutetium-177 Octreotate (177Lu-Octreotate) peptide receptor radionuclide therapy (PRRT) and capecitabine (CAP)/temozolomide (TEM) chemotherapy (chemo): (i) versus CAPTEM alone in the treatment of low to intermediate grade pancreatic neuroendocrin...
   Locations: Royal North Shore Hospital, St Leonards, Australia; Royal Brisbane and Women's Hospital, Herston, Australia; Peter MacCallum Cancer Centre, East Melbourne, Australia
              ... and 1 more locations
----------------------------------------

136. Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma
   NCT ID: NCT03837977
   Status: COMPLETED
   Phase: PHASE2
   Condition: Oncology; Neuroendocrine Carcinoma
   Intervention: Liposomal Irinotecan; Fluorouracil; Folinic Acid; Docetaxel
   Sponsor: The Christie NHS Foundation Trust
   Start Date: 2018-11-13
   Completion Date: 2024-11-26
   Has Posted Results: False
   Publications Count: 1
   Has Publications: Yes
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03837977
   Summary: There is currently no standard treatment beyond first-line etoposide/platinum-based chemotherapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma. Therefore the treatment of patients whose disease progresses on or after this first-line treatment is an area ...
   Locations: The Beaston West of Scotland Cancer Center, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom; Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom
              ... and 1 more locations
----------------------------------------

137. Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
   NCT ID: NCT04505553
   Status: COMPLETED
   Phase: PHASE2
   Condition: Appendix Carcinoma; Colon Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Malignant Digestive System Neoplasm; Pancreatic Carcinoma; Rectal Carcinoma; Small Intestinal Carcinoma; Anal Carcinoma; Digestive System Carcinoma; Digestive System Neuroendocrine Tumor; Pancreatic Neuroendocrine Tumor
   Intervention: Acupuncture Therapy; Acupressure Therapy; Oral Cryotherapy; Questionnaire Administration; Quality-of-Life Assessment
   Sponsor: University of Washington
   Start Date: 2021-06-01
   Completion Date: 2024-03-31
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04505553
   Summary: This phase II trial investigates how well oral cryotherapy plus acupressure and acupuncture compared with oral cryotherapy alone work in decreasing chemotherapy-induced peripheral neuropathy in patients with gastrointestinal cancer who are receiving oxaliplatin-based chemotherapy. Acupressure is the...
   Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, United States
----------------------------------------

138. Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
   NCT ID: NCT03902951
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Metastatic Prostate Adenocarcinoma; Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation; Recurrent Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
   Intervention: Abiraterone Acetate; Apalutamide; Leuprolide Acetate; Quality-of-Life Assessment; Questionnaire Administration; Stereotactic Body Radiation Therapy
   Sponsor: Jonsson Comprehensive Cancer Center
   Start Date: 2021-03-17
   Completion Date: 2027-01-01
   Has Posted Results: False
   Publications Count: 0
   Has Publications: No
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03902951
   Summary: This phase II trial studies how well antiandrogen therapy (leuprolide, apalutamide, and abiraterone acetate) and stereotactic body radiation therapy (SBRT) works in treating patients with prostate cancer that has come back and has spread to other parts of the body. Drugs used in chemotherapy, such a...
   Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, United States
----------------------------------------

